772 lines
No EOL
240 KiB
HTML
772 lines
No EOL
240 KiB
HTML
<?xml version="1.0" encoding="utf-8"?>
|
|
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
|
|
|
|
<head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
|
|
<!-- AppResources meta begin -->
|
|
<meta name="paf-app-resources" content="" />
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- AppResources meta end -->
|
|
|
|
<!-- TemplateResources meta begin -->
|
|
<meta name="paf_template" content="" />
|
|
|
|
<!-- TemplateResources meta end -->
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK66049" /><meta name="ncbi_domain" content="pdqcis" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK66049.2/" /><meta name="ncbi_pagename" content="Fatigue (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
|
|
<!-- Logger end -->
|
|
|
|
<title>Fatigue (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf</title>
|
|
|
|
<!-- AppResources external_resources begin -->
|
|
<link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>
|
|
|
|
<!-- AppResources external_resources end -->
|
|
|
|
<!-- Page meta begin -->
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="PDQ Cancer Information Summaries [Internet]" /><meta name="citation_title" content="Fatigue (PDQ®)" /><meta name="citation_publisher" content="National Cancer Institute (US)" /><meta name="citation_date" content="2017/01/13" /><meta name="citation_author" content="PDQ Supportive and Palliative Care Editorial Board" /><meta name="citation_pmid" content="26389484" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK66049/" /><meta name="citation_keywords" content="fatigue" /><meta name="citation_keywords" content="fatigue" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Fatigue (PDQ®)" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Cancer Institute (US)" /><meta name="DC.Contributor" content="PDQ Supportive and Palliative Care Editorial Board" /><meta name="DC.Date" content="2017/01/13" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK66049/" /><meta name="description" content="Expert-reviewed information summary about fatigue, a condition marked by extreme tiredness and inability to function because of lack of energy, often seen as a complication of cancer or its treatment." /><meta name="og:title" content="Fatigue (PDQ®)" /><meta name="og:type" content="book" /><meta name="og:description" content="Expert-reviewed information summary about fatigue, a condition marked by extreme tiredness and inability to function because of lack of energy, often seen as a complication of cancer or its treatment." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK66049/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-pdqcis-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/pdqcis/CDR0000062734/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK66049/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js?_=3.18"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.26/books.min.js"> </script><meta name="book-collection" content="NONE" />
|
|
|
|
<!-- Page meta end -->
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8B02DD7C9797410000000000590048.m_13" />
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4216701/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/4207974/4206132/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3411343/3882866.css" media="print" /></head>
|
|
<body class="book-part">
|
|
<div class="grid">
|
|
<div class="col twelve_col nomargin shadow">
|
|
<!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
|
|
<div class="sysmessages">
|
|
<noscript>
|
|
<p class="nojs">
|
|
<strong>Warning:</strong>
|
|
The NCBI web site requires JavaScript to function.
|
|
<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
|
|
</p>
|
|
</noscript>
|
|
</div>
|
|
<!--/.sysmessage-->
|
|
<div class="wrap">
|
|
<div class="page">
|
|
<div class="top">
|
|
<div id="universal_header">
|
|
<section class="usa-banner">
|
|
<div class="usa-accordion">
|
|
<header class="usa-banner-header">
|
|
<div class="usa-grid usa-banner-inner">
|
|
<img src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/favicons/favicon-57.png" alt="U.S. flag" />
|
|
<p>An official website of the United States government</p>
|
|
<button class="non-usa-accordion-button usa-banner-button" aria-expanded="false" aria-controls="gov-banner-top" type="button">
|
|
<span class="usa-banner-button-text">Here's how you know</span>
|
|
</button>
|
|
</div>
|
|
</header>
|
|
<div class="usa-banner-content usa-grid usa-accordion-content" id="gov-banner-top" aria-hidden="true">
|
|
<div class="usa-banner-guidance-gov usa-width-one-half">
|
|
<img class="usa-banner-icon usa-media_block-img" src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-dot-gov.svg" alt="Dot gov" />
|
|
<div class="usa-media_block-body">
|
|
<p>
|
|
<strong>The .gov means it's official.</strong>
|
|
<br />
|
|
Federal government websites often end in .gov or .mil. Before
|
|
sharing sensitive information, make sure you're on a federal
|
|
government site.
|
|
</p>
|
|
</div>
|
|
</div>
|
|
<div class="usa-banner-guidance-ssl usa-width-one-half">
|
|
<img class="usa-banner-icon usa-media_block-img" src="https://www.ncbi.nlm.nih.gov/coreutils/uswds/img/icon-https.svg" alt="Https" />
|
|
<div class="usa-media_block-body">
|
|
<p>
|
|
<strong>The site is secure.</strong>
|
|
<br />
|
|
The <strong>https://</strong> ensures that you are connecting to the
|
|
official website and that any information you provide is encrypted
|
|
and transmitted securely.
|
|
</p>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
</section>
|
|
<div class="usa-overlay"></div>
|
|
<header class="ncbi-header" role="banner" data-section="Header">
|
|
|
|
<div class="usa-grid">
|
|
<div class="usa-width-one-whole">
|
|
|
|
<div class="ncbi-header__logo">
|
|
<a href="/" class="logo" aria-label="NCBI Logo" data-ga-action="click_image" data-ga-label="NIH NLM Logo">
|
|
<img src="https://www.ncbi.nlm.nih.gov/coreutils/nwds/img/logos/AgencyLogo.svg" alt="NIH NLM Logo" />
|
|
</a>
|
|
</div>
|
|
|
|
<div class="ncbi-header__account">
|
|
<a id="account_login" href="https://account.ncbi.nlm.nih.gov" class="usa-button header-button" style="display:none" data-ga-action="open_menu" data-ga-label="account_menu">Log in</a>
|
|
<button id="account_info" class="header-button" style="display:none" aria-controls="account_popup" type="button">
|
|
<span class="fa fa-user" aria-hidden="true">
|
|
<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" width="20px" height="20px">
|
|
<g style="fill: #fff">
|
|
<ellipse cx="12" cy="8" rx="5" ry="6"></ellipse>
|
|
<path d="M21.8,19.1c-0.9-1.8-2.6-3.3-4.8-4.2c-0.6-0.2-1.3-0.2-1.8,0.1c-1,0.6-2,0.9-3.2,0.9s-2.2-0.3-3.2-0.9 C8.3,14.8,7.6,14.7,7,15c-2.2,0.9-3.9,2.4-4.8,4.2C1.5,20.5,2.6,22,4.1,22h15.8C21.4,22,22.5,20.5,21.8,19.1z"></path>
|
|
</g>
|
|
</svg>
|
|
</span>
|
|
<span class="username desktop-only" aria-hidden="true" id="uname_short"></span>
|
|
<span class="sr-only">Show account info</span>
|
|
</button>
|
|
</div>
|
|
|
|
<div class="ncbi-popup-anchor">
|
|
<div class="ncbi-popup account-popup" id="account_popup" aria-hidden="true">
|
|
<div class="ncbi-popup-head">
|
|
<button class="ncbi-close-button" data-ga-action="close_menu" data-ga-label="account_menu" type="button">
|
|
<span class="fa fa-times">
|
|
<svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 48 48" width="24px" height="24px">
|
|
<path d="M38 12.83l-2.83-2.83-11.17 11.17-11.17-11.17-2.83 2.83 11.17 11.17-11.17 11.17 2.83 2.83 11.17-11.17 11.17 11.17 2.83-2.83-11.17-11.17z"></path>
|
|
</svg>
|
|
</span>
|
|
<span class="usa-sr-only">Close</span></button>
|
|
<h4>Account</h4>
|
|
</div>
|
|
<div class="account-user-info">
|
|
Logged in as:<br />
|
|
<b><span class="username" id="uname_long">username</span></b>
|
|
</div>
|
|
<div class="account-links">
|
|
<ul class="usa-unstyled-list">
|
|
<li><a id="account_myncbi" href="/myncbi/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_myncbi">Dashboard</a></li>
|
|
<li><a id="account_pubs" href="/myncbi/collections/bibliography/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_pubs">Publications</a></li>
|
|
<li><a id="account_settings" href="/account/settings/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_settings">Account settings</a></li>
|
|
<li><a id="account_logout" href="/account/signout/" class="set-base-url" data-ga-action="click_menu_item" data-ga-label="account_logout">Log out</a></li>
|
|
</ul>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
|
|
</div>
|
|
</div>
|
|
</header>
|
|
<div role="navigation" aria-label="access keys">
|
|
<a id="nws_header_accesskey_0" href="https://www.ncbi.nlm.nih.gov/guide/browsers/#ncbi_accesskeys" class="usa-sr-only" accesskey="0" tabindex="-1">Access keys</a>
|
|
<a id="nws_header_accesskey_1" href="https://www.ncbi.nlm.nih.gov" class="usa-sr-only" accesskey="1" tabindex="-1">NCBI Homepage</a>
|
|
<a id="nws_header_accesskey_2" href="/myncbi/" class="set-base-url usa-sr-only" accesskey="2" tabindex="-1">MyNCBI Homepage</a>
|
|
<a id="nws_header_accesskey_3" href="#maincontent" class="usa-sr-only" accesskey="3" tabindex="-1">Main Content</a>
|
|
<a id="nws_header_accesskey_4" href="#" class="usa-sr-only" accesskey="4" tabindex="-1">Main Navigation</a>
|
|
</div>
|
|
<section data-section="Alerts">
|
|
<div class="ncbi-alerts-placeholder"></div>
|
|
</section>
|
|
</div>
|
|
<div class="header">
|
|
<div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
|
|
<div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" data-ac_dict="bookshelf-search">Books</option><option value="nlmcatalog">NLM Catalog</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed" class="last">PubMed</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
|
|
<a href="/books/browse/">Browse Titles</a>
|
|
</li><li>
|
|
<a href="/books/advanced/">Advanced</a>
|
|
</li><li class="help">
|
|
<a href="/books/NBK3833/">Help</a>
|
|
</li><li class="disclaimer">
|
|
<a target="_blank" data-ga-category="literature_resources" data-ga-action="link_click" data-ga-label="disclaimer_link" href="https://www.ncbi.nlm.nih.gov/books/about/disclaimer/">Disclaimer</a>
|
|
</li></ul></div>
|
|
</div>
|
|
|
|
|
|
|
|
<!--<component id="Page" label="headcontent"/>-->
|
|
|
|
</div>
|
|
<div class="content">
|
|
<!-- site messages -->
|
|
<!-- Custom content 1 -->
|
|
<div class="col1">
|
|
|
|
</div>
|
|
|
|
<div class="container">
|
|
<div id="maincontent" class="content eight_col col">
|
|
<!-- Custom content in the left column above book nav -->
|
|
<div class="col2">
|
|
|
|
</div>
|
|
|
|
<!-- Book content -->
|
|
|
|
|
|
<!-- Custom content between navigation and content -->
|
|
<div class="col3">
|
|
|
|
</div>
|
|
|
|
<div class="document">
|
|
<div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="Table of Contents Page" href="/books/n/pdqcis/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-pdqcis-lrg.png" alt="Cover of PDQ Cancer Information Summaries" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>PDQ Cancer Information Summaries [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK66049_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK66049_dtls__"><div>Bethesda (MD): <a href="http://www.cancer.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Cancer Institute (US)</a>; 2002-.</div></div><div class="half_rhythm"></div><div class="bk_noprnt"><form method="get" action="/books/n/pdqcis/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div></div></div></div>
|
|
<div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK66049_"><span class="title" itemprop="name">Fatigue (PDQ®)</span></h1><div class="subtitle whole_rhythm">Health Professional Version</div><p class="contrib-group"><span itemprop="author">PDQ Supportive and Palliative Care Editorial Board</span>.</p><p class="small">Published online: January 13, 2017.</p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="_abs_rndgid_" itemprop="description"><p id="CDR0000062734__392">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the pathophysiology and treatment of fatigue. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.</p><p id="CDR0000062734__393">This summary is reviewed regularly and updated as necessary by the PDQ Supportive and Palliative Care Editorial Board, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</p></div><div id="CDR0000062734__1"><h2 id="_CDR0000062734__1_">Overview</h2><p id="CDR0000062734__2">Fatigue is the most common side effect of cancer treatment with chemotherapy, radiation therapy, or selected biologic response modifiers.[<a class="bk_pop" href="#CDR0000062734_rl_1_1">1</a>] Cancer treatment–related fatigue generally improves after therapy is completed, but some level of fatigue may persist for months or years following treatment. Research indicates that for at least a subset of patients, fatigue may be a significant issue long into survivorship.[<a class="bk_pop" href="#CDR0000062734_rl_1_2">2</a>,<a class="bk_pop" href="#CDR0000062734_rl_1_3">3</a>] Fatigue is also seen as a presenting symptom in cancers that produce problems such as anemia, endocrine changes, and respiratory obstruction and is common in people with advanced cancer who are not undergoing active cancer treatment. Cancer treatment–related fatigue is reported in 14% to 96% of patients undergoing cancer treatment [<a class="bk_pop" href="#CDR0000062734_rl_1_4">4</a>-<a class="bk_pop" href="#CDR0000062734_rl_1_10">10</a>] and in 19% to 82% of patients posttreatment.[<a class="bk_pop" href="#CDR0000062734_rl_1_1">1</a>,<a class="bk_pop" href="#CDR0000062734_rl_1_2">2</a>]</p><p id="CDR0000062734__237"> Several studies have documented significantly worse fatigue in cancer survivors compared with noncancer populations, as described in one review article.[<a class="bk_pop" href="#CDR0000062734_rl_1_1">1</a>] For example, a Norwegian cross-sectional study [<a class="bk_pop" href="#CDR0000062734_rl_1_11">11</a>] compared the prevalence of fatigue in long-term survivors of testicular cancer (n = 1,431) at an average of 11 years posttreatment with the prevalence of fatigue in age-matched men in the general Norwegian population (n = 1,080). The prevalence of chronic cancer-related fatigue (CRF) was 17.1% (95% confidence interval [CI], 15.2–19.1%) among testicular cancer survivors, compared with 9.7% (95% CI, 8.0–11.5%) in the general population. Chronic CRF was also associated with multiple psychosocial problems, somatic complaints, and poor quality of life.[<a class="bk_pop" href="#CDR0000062734_rl_1_11">11</a>]</p><p id="CDR0000062734__154">Fatigue, like pain, is viewed as a self-perceived state. Patients may describe fatigue as feeling:[<a class="bk_pop" href="#CDR0000062734_rl_1_12">12</a>]</p><ul id="CDR0000062734__330"><li class="half_rhythm"><div>Tired.</div></li><li class="half_rhythm"><div>Weak.</div></li><li class="half_rhythm"><div>
|
|
Exhausted.</div></li><li class="half_rhythm"><div> Lazy.</div></li><li class="half_rhythm"><div>Weary.</div></li><li class="half_rhythm"><div>Worn-out.</div></li><li class="half_rhythm"><div>Heavy.</div></li><li class="half_rhythm"><div>Slow.</div></li><li class="half_rhythm"><div>Like they do not have any energy or any get-up-and-go.</div></li></ul><p id="CDR0000062734__331">Health
|
|
professionals have included fatigue within concepts such as: </p><ul id="CDR0000062734__332"><li class="half_rhythm"><div>Asthenia.</div></li><li class="half_rhythm"><div>
|
|
Lassitude.</div></li><li class="half_rhythm"><div>Malaise.</div></li><li class="half_rhythm"><div>Prostration.</div></li><li class="half_rhythm"><div>Exercise intolerance.</div></li><li class="half_rhythm"><div> Lack of energy.</div></li><li class="half_rhythm"><div>Weakness.</div></li></ul><p id="CDR0000062734__333">Research on fatigue in people with cancer has included primarily self-reports of fatigue, with fewer but increasing data exploring biologic or physiologic correlates. Such correlates have included measures of muscle weakness, maximal oxygen uptake, cytokines, and cortisol.</p><p id="CDR0000062734__155">Fatigue experienced as a side effect of cancer treatment is differentiated from fatigue experienced by healthy people in their daily lives. <i>Healthy fatigue</i> is frequently described as acute fatigue that is eventually relieved by sleep and rest; cancer treatment–related fatigue is categorized as chronic fatigue because it is present over a long period of time, interferes with functioning, and is not completely relieved by sleep and rest.[<a class="bk_pop" href="#CDR0000062734_rl_1_13">13</a>] Also, the level of CRF is often disproportionate to the level of activity or energy exerted.[<a class="bk_pop" href="#CDR0000062734_rl_1_13">13</a>] Although the label <i>chronic fatigue</i> is accurate, using this label does not mean that people with cancer who experience fatigue have chronic fatigue syndrome. Using the phrase <i>chronic fatigue</i> can be confusing to both patients and health professionals. Terms such as <i>cancer fatigue</i>, <i>cancer-related fatigue</i>, and <i>cancer treatment–related fatigue</i> have all been used in the clinical literature, research literature, and educational materials for patients and the public.</p><p id="CDR0000062734__156">Fatigue has a negative impact on all areas of function, including the following:[<a class="bk_pop" href="#CDR0000062734_rl_1_14">14</a>-<a class="bk_pop" href="#CDR0000062734_rl_1_17">17</a>]</p><ul id="CDR0000062734__334"><li class="half_rhythm"><div> Mood.</div></li><li class="half_rhythm"><div>Physical function.</div></li><li class="half_rhythm"><div>Work performance.</div></li><li class="half_rhythm"><div>Social interaction.</div></li><li class="half_rhythm"><div>Family care.[<a class="bk_pop" href="#CDR0000062734_rl_1_18">18</a>]</div></li><li class="half_rhythm"><div> Cognitive performance.</div></li><li class="half_rhythm"><div>School work.</div></li><li class="half_rhythm"><div>Community activities.</div></li><li class="half_rhythm"><div>Sense of self.</div></li></ul><p id="CDR0000062734__335">The pattern of fatigue associated with cancer treatment varies according to type and schedule of treatment. For example, people treated with cyclic chemotherapy regimens generally exhibit peak fatigue in the days following treatment, then report lower levels of fatigue until the next treatment; however, those undergoing external-beam radiation therapy report gradually increasing fatigue over the course of therapy of the largest treatment field. Few studies of people undergoing cancer treatment have addressed the issue of fatigue as a result of the emotional distress associated with undergoing a diagnostic evaluation for cancer and the effects of medical and surgical procedures used for that evaluation and for initial treatment. Because most adults enter the cancer care system following at least one surgical procedure and because surgery and emotional distress are both associated with fatigue, it is likely that most people beginning nonsurgical treatment are experiencing fatigue at the beginning of treatment.[<a class="bk_pop" href="#CDR0000062734_rl_1_19">19</a>,<a class="bk_pop" href="#CDR0000062734_rl_1_20">20</a>]</p><p id="CDR0000062734__160">Recommendations for fatigue management focus on identifying factors that may be contributing to fatigue. Because the only definitive causal mechanism demonstrated through research to date is chemotherapy-induced anemia, most clinical recommendations for managing fatigue caused by something other than chemotherapy-induced anemia rely on careful development of clinical hypotheses, as outlined in the National Comprehensive Cancer Network guidelines on fatigue.[<a class="bk_pop" href="#CDR0000062734_rl_1_21">21</a>] The only level 1 intervention for CRF at this time is exercise. (Refer to the <a href="#CDR0000062734__94">Exercise</a> section of this summary for more information.) Much more research is needed to better define fatigue and its trajectory, understand its physiology, and determine the best ways to prevent and treat it.</p><p id="CDR0000062734__1_4">In this summary, unless otherwise stated, evidence and practice issues as they relate to adults are discussed. The evidence and application to practice related to children may differ significantly from information related to adults. When specific information about the care of children is available, it is summarized under its own heading.</p><div id="CDR0000062734_rl_1"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062734_rl_1_1">Prue G, Rankin J, Allen J, et al.: Cancer-related fatigue: A critical appraisal. Eur J Cancer 42 (7): 846-63, 2006. [<a href="https://pubmed.ncbi.nlm.nih.gov/16460928" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16460928</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_1_2">Bower JE, Ganz PA, Desmond KA, et al.: Fatigue in long-term breast carcinoma survivors: a longitudinal investigation. Cancer 106 (4): 751-8, 2006. [<a href="https://pubmed.ncbi.nlm.nih.gov/16400678" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16400678</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_1_3">Baker F, Denniston M, Smith T, et al.: Adult cancer survivors: how are they faring? Cancer 104 (11 Suppl): 2565-76, 2005. [<a href="https://pubmed.ncbi.nlm.nih.gov/16258929" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16258929</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_1_4">Fosså SD, Dahl AA, Loge JH: Fatigue, anxiety, and depression in long-term survivors of testicular cancer. J Clin Oncol 21 (7): 1249-54, 2003. [<a href="https://pubmed.ncbi.nlm.nih.gov/12663711" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12663711</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_1_5">Miaskowski C, Portenoy RK: Update on the assessment and management of cancer-related fatigue. Principles and Practice of Supportive Oncology Updates 1 (2): 1-10, 1998.</div></li><li><div class="bk_ref" id="CDR0000062734_rl_1_6">Irvine DM, Vincent L, Bubela N, et al.: A critical appraisal of the research literature investigating fatigue in the individual with cancer. Cancer Nurs 14 (4): 188-99, 1991. [<a href="https://pubmed.ncbi.nlm.nih.gov/1913633" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1913633</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_1_7">Vogelzang NJ, Breitbart W, Cella D, et al.: Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 34 (3 Suppl 2): 4-12, 1997. [<a href="https://pubmed.ncbi.nlm.nih.gov/9253778" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9253778</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_1_8">Detmar SB, Aaronson NK, Wever LD, et al.: How are you feeling? Who wants to know? Patients' and oncologists' preferences for discussing health-related quality-of-life issues. J Clin Oncol 18 (18): 3295-301, 2000. [<a href="https://pubmed.ncbi.nlm.nih.gov/10986063" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10986063</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_1_9">Costantini M, Mencaglia E, Giulio PD, et al.: Cancer patients as 'experts' in defining quality of life domains. A multicentre survey by the Italian Group for the Evaluation of Outcomes in Oncology (IGEO). Qual Life Res 9 (2): 151-9, 2000. [<a href="https://pubmed.ncbi.nlm.nih.gov/10983479" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10983479</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_1_10">Cella D, Lai JS, Chang CH, et al.: Fatigue in cancer patients compared with fatigue in the general United States population. Cancer 94 (2): 528-38, 2002. [<a href="https://pubmed.ncbi.nlm.nih.gov/11900238" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11900238</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_1_11">Orre IJ, Fosså SD, Murison R, et al.: Chronic cancer-related fatigue in long-term survivors of testicular cancer. J Psychosom Res 64 (4): 363-71, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18374735" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18374735</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_1_12">Barsevick AM, Whitmer K, Walker L: In their own words: using the common sense model to analyze patient descriptions of cancer-related fatigue. Oncol Nurs Forum 28 (9): 1363-9, 2001. [<a href="https://pubmed.ncbi.nlm.nih.gov/11683307" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11683307</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_1_13">Berger AM, Abernethy AP, Atkinson A, et al.: Cancer-related fatigue. J Natl Compr Canc Netw 8 (8): 904-31, 2010. [<a href="https://pubmed.ncbi.nlm.nih.gov/20870636" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20870636</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_1_14">Pickard-Holley S: Fatigue in cancer patients. A descriptive study. Cancer Nurs 14 (1): 13-9, 1991. [<a href="https://pubmed.ncbi.nlm.nih.gov/2013047" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2013047</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_1_15">Glaus A: Assessment of fatigue in cancer and non-cancer patients and in healthy individuals. Support Care Cancer 1 (6): 305-15, 1993. [<a href="https://pubmed.ncbi.nlm.nih.gov/8156248" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8156248</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_1_16">Given B, Given CW, McCorkle R, et al.: Pain and fatigue management: results of a nursing randomized clinical trial. Oncol Nurs Forum 29 (6): 949-56, 2002. [<a href="https://pubmed.ncbi.nlm.nih.gov/12096292" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12096292</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_1_17">Curt GA: The impact of fatigue on patients with cancer: overview of FATIGUE 1 and 2. Oncologist 5 (Suppl 2): 9-12, 2000. [<a href="https://pubmed.ncbi.nlm.nih.gov/10896323" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10896323</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_1_18">Passik SD, Kirsh KL: A pilot examination of the impact of cancer patients' fatigue on their spousal caregivers. Palliat Support Care 3 (4): 273-9, 2005. [<a href="https://pubmed.ncbi.nlm.nih.gov/17039982" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17039982</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_1_19">Ancoli-Israel S, Liu L, Marler MR, et al.: Fatigue, sleep, and circadian rhythms prior to chemotherapy for breast cancer. Support Care Cancer 14 (3): 201-9, 2006. [<a href="/pmc/articles/PMC1599708/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1599708</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16010529" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16010529</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_1_20">Jacobsen PB, Hann DM, Azzarello LM, et al.: Fatigue in women receiving adjuvant chemotherapy for breast cancer: characteristics, course, and correlates. J Pain Symptom Manage 18 (4): 233-42, 1999. [<a href="https://pubmed.ncbi.nlm.nih.gov/10534963" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10534963</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_1_21">National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Cancer-Related Fatigue. Version 1.2017. Fort Washington, Pa: National Comprehensive Cancer Network, 2017. <a href="https://www.nccn.org/professionals/physician_gls/pdf/fatigue.pdf" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">Available online with free registration</a>. Last accessed January 12, 2017.</div></li></ol></div></div><div id="CDR0000062734__7"><h2 id="_CDR0000062734__7_">Pathogenesis of Fatigue</h2><p id="CDR0000062734__8">Except for chemotherapy-induced anemia, the mechanisms responsible for fatigue in people with cancer are not known. Understanding the causes of fatigue in people with cancer is especially challenging because each individual may experience multiple possible causes of fatigue simultaneously. This multifactorial etiologic hypothesis is apparent in the various models that have been proposed for the study of fatigue.[<a class="bk_pop" href="#CDR0000062734_rl_7_1">1</a>,<a class="bk_pop" href="#CDR0000062734_rl_7_2">2</a>]
|
|
Energy balance, stress, life demands, sleep, neurophysiologic changes, disruption of circadian rhythms, cardiac issues, and neuroimmunologic changes are generally incorporated in these models, based on the rationale that these factors are associated with fatigue in contexts other than cancer.[<a class="bk_pop" href="#CDR0000062734_rl_7_3">3</a>] The cancer literature supports some of these variables.</p><p id="CDR0000062734__254">There is a burgeoning amount of evidence, particularly in women with breast cancer and men with prostate cancer, that fatigue is associated with markers of increased immune inflammatory activity. When fatigued individuals with a history of breast cancer are compared with breast cancer survivors without fatigue, different patterns emerge with respect to interleukin-6, interleukin-1 receptor antagonist, C-reactive protein, neopterin, and soluble tumor necrosis factor receptor-II.[<a class="bk_pop" href="#CDR0000062734_rl_7_4">4</a>-<a class="bk_pop" href="#CDR0000062734_rl_7_6">6</a>] Although the precise relationships—and the clinical meaning of those relationships—are not yet known, increased cytokines likely contribute to the symptoms of asthenia, fatigue, and lethargy, as supported in animal models of cytokine-induced sickness behavior [<a class="bk_pop" href="#CDR0000062734_rl_7_7">7</a>,<a class="bk_pop" href="#CDR0000062734_rl_7_8">8</a>] and in humans.[<a class="bk_pop" href="#CDR0000062734_rl_7_9">9</a>] There have not yet been large, well-controlled studies that have evaluated the effects of general anti-inflammatory agents on fatigue or cytokine biomarkers.</p><p id="CDR0000062734__255"> Other studies demonstrate a change in the regulation of cortisol by the hypothalamic pituitary adrenal axis. One key study put fatigued and nonfatigued breast cancer survivors through a stress battery in a laboratory setting. Nonfatigued survivors mounted a significant cortisol increase in response to acute stress, while fatigued survivors had a very blunted response.[<a class="bk_pop" href="#CDR0000062734_rl_7_10">10</a>] Another study has shown fatigued breast cancer survivors have flattened cortisol slopes, having higher levels of cortisol at the end of the day than do nonfatigued survivors.[<a class="bk_pop" href="#CDR0000062734_rl_7_11">11</a>] It is the dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis that may account for the prolonged inflammatory cytokine milieu; understanding the body’s response to numerous chronic stressors in cancer may help in managing fatigue.</p><p id="CDR0000062734__257">Finally, another theory is that serotonin is negatively impacted through chronic exposure to proinflammatory cytokines. One hypothesis is that the relationship between central nervous system concentrations of serotonin and fatigue have a U-shaped relationship, suggesting that very high and very low levels of serotonin may be associated with cancer-related fatigue.[<a class="bk_pop" href="#CDR0000062734_rl_7_12">12</a>] However, studies that have evaluated serotonergic agents have not demonstrated a benefit for fatigue.[<a class="bk_pop" href="#CDR0000062734_rl_7_2">2</a>] The role and relationship of many important neurotransmitters such as dopamine, norepinephrine, and serotonin with HPA axis functioning and cytokine expression have yet to be fully understood.</p><div id="CDR0000062734_rl_7"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062734_rl_7_1">Miaskowski C, Portenoy RK: Update on the assessment and management of cancer-related fatigue. Principles and Practice of Supportive Oncology Updates 1 (2): 1-10, 1998.</div></li><li><div class="bk_ref" id="CDR0000062734_rl_7_2">Morrow GR, Andrews PL, Hickok JT, et al.: Fatigue associated with cancer and its treatment. Support Care Cancer 10 (5): 389-98, 2002. [<a href="https://pubmed.ncbi.nlm.nih.gov/12136222" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12136222</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_7_3">Aistars J: Fatigue in the cancer patient: a conceptual approach to a clinical problem. Oncol Nurs Forum 14 (6): 25-30, 1987 Nov-Dec. [<a href="https://pubmed.ncbi.nlm.nih.gov/3320982" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3320982</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_7_4">Bower JE, Ganz PA, Aziz N, et al.: Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med 64 (4): 604-11, 2002 Jul-Aug. [<a href="https://pubmed.ncbi.nlm.nih.gov/12140350" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12140350</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_7_5">Evans WJ, Lambert CP: Physiological basis of fatigue. Am J Phys Med Rehabil 86 (1 Suppl): S29-46, 2007. [<a href="https://pubmed.ncbi.nlm.nih.gov/17370370" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17370370</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_7_6">Bower JE, Ganz PA, Tao ML, et al.: Inflammatory biomarkers and fatigue during radiation therapy for breast and prostate cancer. Clin Cancer Res 15 (17): 5534-40, 2009. [<a href="/pmc/articles/PMC2884979/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2884979</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19706826" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19706826</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_7_7">Dantzer R: Cytokine-induced sickness behavior: mechanisms and implications. Ann N Y Acad Sci 933: 222-34, 2001. [<a href="https://pubmed.ncbi.nlm.nih.gov/12000023" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12000023</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_7_8">Hart BL: Biological basis of the behavior of sick animals. Neurosci Biobehav Rev 12 (2): 123-37, 1988. [<a href="https://pubmed.ncbi.nlm.nih.gov/3050629" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3050629</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_7_9">Eisenberger NI, Inagaki TK, Mashal NM, et al.: Inflammation and social experience: an inflammatory challenge induces feelings of social disconnection in addition to depressed mood. Brain Behav Immun 24 (4): 558-63, 2010. [<a href="/pmc/articles/PMC2856755/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2856755</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20043983" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20043983</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_7_10">Bower JE, Ganz PA, Aziz N: Altered cortisol response to psychologic stress in breast cancer survivors with persistent fatigue. Psychosom Med 67 (2): 277-80, 2005 Mar-Apr. [<a href="https://pubmed.ncbi.nlm.nih.gov/15784794" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15784794</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_7_11">Bower JE, Ganz PA, Dickerson SS, et al.: Diurnal cortisol rhythm and fatigue in breast cancer survivors. Psychoneuroendocrinology 30 (1): 92-100, 2005. [<a href="https://pubmed.ncbi.nlm.nih.gov/15358446" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15358446</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_7_12">Jager A, Sleijfer S, van der Rijt CC: The pathogenesis of cancer related fatigue: could increased activity of pro-inflammatory cytokines be the common denominator? Eur J Cancer 44 (2): 175-81, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18162394" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18162394</span></a>]</div></li></ol></div></div><div id="CDR0000062734__12"><h2 id="_CDR0000062734__12_">Contributing Factors</h2><p id="CDR0000062734__13">Although fatigue is clearly prevalent in patients with cancer, it has been
|
|
difficult to identify consistent correlates of fatigue in this patient
|
|
population. The factors most often implicated have been the following:[<a class="bk_pop" href="#CDR0000062734_rl_12_1">1</a>-<a class="bk_pop" href="#CDR0000062734_rl_12_9">9</a>]</p><ul id="CDR0000062734__136"><li class="half_rhythm"><div>Cancer
|
|
treatment.</div></li><li class="half_rhythm"><div>Anemia. </div></li><li class="half_rhythm"><div>Medications.</div></li><li class="half_rhythm"><div>Cachexia/anorexia.</div></li><li class="half_rhythm"><div>Metabolic disturbances.</div></li><li class="half_rhythm"><div>Hormone deficiency or excess.</div></li><li class="half_rhythm"><div>Psychological distress.</div></li><li class="half_rhythm"><div>Physical deconditioning.</div></li><li class="half_rhythm"><div>Sleep disturbances.</div></li><li class="half_rhythm"><div>Excessive
|
|
inactivity.</div></li><li class="half_rhythm"><div>Pulmonary impairment.</div></li><li class="half_rhythm"><div>Neuromuscular dysfunction.</div></li><li class="half_rhythm"><div>Pain and other symptoms.</div></li><li class="half_rhythm"><div>Proinflammatory cytokines.</div></li><li class="half_rhythm"><div>Nutritional deficiencies.</div></li><li class="half_rhythm"><div>Dehydration.</div></li><li class="half_rhythm"><div> Infection.</div></li><li class="half_rhythm"><div>Concomitant medical illness.</div></li><li class="half_rhythm"><div>Cardiac impairment.</div></li></ul><div id="CDR0000062734__14"><h3>Cancer Treatment</h3><p id="CDR0000062734__171">The association of fatigue with the major cancer treatment modalities of surgery, chemotherapy, radiation therapy, and biologic response modifier therapy caused speculation that fatigue resulted from tissue damage or accumulation of the products of cell death. Interest in the effects of cancer treatment on the production of proinflammatory cytokines is based on recognition of the strong fatigue-inducing effect of some biologic response modifiers such as interferon-alpha and the finding of elevated levels of proinflammatory cytokines in people experiencing persistent fatigue following cancer treatment.[<a class="bk_pop" href="#CDR0000062734_rl_12_10">10</a>,<a class="bk_pop" href="#CDR0000062734_rl_12_11">11</a>]</p><p id="CDR0000062734__252">Many people with cancer undergo surgery for diagnosis or treatment. Despite the high incidence of postoperative fatigue observed in clinical practice, little research exists that examines causes and correlates of postoperative fatigue in people with cancer.[<a class="bk_pop" href="#CDR0000062734_rl_12_12">12</a>] It is clear, however, that fatigue is a problem postsurgery that improves with time and is compounded by fatigue experienced from other cancer treatments.[<a class="bk_pop" href="#CDR0000062734_rl_12_12">12</a>]</p><p id="CDR0000062734__17">Fatigue has long been associated with radiation exposure and is reported as being one of the most common and activity-limiting side effect of radiation therapy for cancer.[<a class="bk_pop" href="#CDR0000062734_rl_12_4">4</a>,<a class="bk_pop" href="#CDR0000062734_rl_12_13">13</a>] Most of the research describing the fatigue trajectory during radiation therapy has been conducted with women who have breast cancer and men who have prostate cancer.[<a class="bk_pop" href="#CDR0000062734_rl_12_13">13</a>,<a class="bk_pop" href="#CDR0000062734_rl_12_14">14</a>] Fatigue increases throughout radiation therapy, peaking around mid course; it remains at this level until radiation therapy is completed, improving somewhat during the 2 months after completion of treatment.[<a class="bk_pop" href="#CDR0000062734_rl_12_13">13</a>-<a class="bk_pop" href="#CDR0000062734_rl_12_15">15</a>] A study that investigated the trajectory of fatigue in men (n = 82) who were undergoing radiation therapy for prostate cancer found significant interindividual variability.[<a class="bk_pop" href="#CDR0000062734_rl_12_14">14</a>] The authors used hierarchical linear modeling, a highly sophisticated analytical method, to identify predictors for prolonged fatigue trajectories. Younger men with a high level of fatigue at radiation therapy initiation were at increased risk of higher levels of morning and evening fatigue during the course of radiation therapy. Additionally, level of depression at radiation therapy initiation predicted the level of morning fatigue during the course of radiation therapy.[<a class="bk_pop" href="#CDR0000062734_rl_12_14">14</a>]</p><p id="CDR0000062734__258">A second study that included 73 women who were undergoing adjuvant radiation therapy for breast cancer found similar differences in the patterns and predictors of morning versus evening fatigue.[<a class="bk_pop" href="#CDR0000062734_rl_12_16">16</a>] Participants were recruited to the study at the time of their simulation visit and completed baseline questionnaires. Data were then collected on 2 subsequent days, in the morning and at bedtime, each week during radiation therapy; every 2 weeks for 2 months after radiation therapy; and once a month for 2 additional months thereafter. Fatigue was measured with the Lee Fatigue Scale. For the group as a whole, over the 25 weeks of data collection, morning fatigue decreased slightly during radiation therapy and was constant for 4 months afterwards, while evening fatigue increased through radiation therapy and then declined slightly after treatment. Evening fatigue was higher for those who:</p><ul id="CDR0000062734__292"><li class="half_rhythm"><div>Were working.</div></li><li class="half_rhythm"><div>Had children at home.</div></li><li class="half_rhythm"><div>Had higher depression scores.</div></li></ul><p id="CDR0000062734__293">Morning fatigue was higher for those who:</p><ul id="CDR0000062734__294"><li class="half_rhythm"><div>Had more trait anxiety.</div></li><li class="half_rhythm"><div>Were experiencing sleep disturbance.</div></li><li class="half_rhythm"><div>Were younger.</div></li><li class="half_rhythm"><div>Had lower body mass indices.</div></li></ul><p id="CDR0000062734__295">Advanced disease and comorbidities also added to the severity of morning fatigue.[<a class="bk_pop" href="#CDR0000062734_rl_12_16">16</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663087/" class="def">Level of evidence: III</a>]</p><p id="CDR0000062734__217"> A
|
|
number of research studies document the existence of a fatigue syndrome that is
|
|
not specific to the disease type or radiation site and that
|
|
demonstrates a gradual decline in fatigue in the patient after treatment is
|
|
completed.[<a class="bk_pop" href="#CDR0000062734_rl_12_15">15</a>,<a class="bk_pop" href="#CDR0000062734_rl_12_17">17</a>-<a class="bk_pop" href="#CDR0000062734_rl_12_20">20</a>] Some of these studies suggest, however, that not all
|
|
patients return to pretreatment energy levels. Specific etiologic factors and
|
|
correlates of fatigue associated with radiation therapy have not been
|
|
identified.[<a class="bk_pop" href="#CDR0000062734_rl_12_12">12</a>] Risk factors for persistent low energy in cancer patients
|
|
include older age, advanced disease, and combination-modality therapy.[<a class="bk_pop" href="#CDR0000062734_rl_12_21">21</a>]
|
|
</p><p id="CDR0000062734__18">Fatigue is a dose-limiting toxicity of treatment with a variety of
|
|
biotherapeutic agents. Biotherapy exposes patients with cancer to exogenous
|
|
and endogenous cytokines.[<a class="bk_pop" href="#CDR0000062734_rl_12_22">22</a>] Biotherapy-related fatigue usually occurs as
|
|
part of a constellation of symptoms called flulike syndrome. This syndrome
|
|
includes:[<a class="bk_pop" href="#CDR0000062734_rl_12_23">23</a>]</p><ul id="CDR0000062734__336"><li class="half_rhythm"><div> Fatigue.</div></li><li class="half_rhythm"><div>Fever.</div></li><li class="half_rhythm"><div> Chills.</div></li><li class="half_rhythm"><div> Myalgias.</div></li><li class="half_rhythm"><div>Headache.</div></li><li class="half_rhythm"><div> Malaise.</div></li></ul><p id="CDR0000062734__337">Mental
|
|
fatigue and cognitive deficits have also been identified as biotherapy side
|
|
effects.[<a class="bk_pop" href="#CDR0000062734_rl_12_24">24</a>] The type of biotherapeutic agent used may influence the type and
|
|
pattern of fatigue experienced.
|
|
</p><p id="CDR0000062734__253">Treatment with chemotherapy is a predictor of fatigue and can be exacerbated by the coexistence of pain, depression, and/or anxiety.[<a class="bk_pop" href="#CDR0000062734_rl_12_25">25</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663072/" class="def">Level of evidence: II</a>][<a class="bk_pop" href="#CDR0000062734_rl_12_26">26</a>] A longitudinal, descriptive study reported highest levels of fatigue at the midpoint of a patient’s chemotherapy cycles, with fatigue improving after treatment but not quite returning to baseline levels 30 days after the last treatment.[<a class="bk_pop" href="#CDR0000062734_rl_12_25">25</a>] In another longitudinal study of women with stage 0 to stage II breast cancer who received chemotherapy with or without radiation therapy (N = 103) versus radiation therapy alone (N = 102) versus a control group (N = 193),[<a class="bk_pop" href="#CDR0000062734_rl_12_27">27</a>] increases in fatigue were demonstrated 3 years posttreatment for the group that received chemotherapy with or without radiation therapy, compared with the two other groups. Mean scores for fatigue severity as measured by the Fatigue Symptom Inventory (range, 0–10) increased over the 3 years as follows:</p><ul id="CDR0000062734__327"><li class="half_rhythm"><div>From 2.31 to 2.86 in the group that received chemotherapy with or without radiation.</div></li><li class="half_rhythm"><div>Only from 1.96 to 2.06 in the radiation therapy–alone group.</div></li><li class="half_rhythm"><div>Only from 2.20 to 2.22 in the noncancer control group.</div></li></ul><p id="CDR0000062734__326">There were statistically significant group-by-time effects for the group that received chemotherapy with or without radiation therapy. This increase in fatigue was not explained by hormone therapy and approached clinically meaningful values.[<a class="bk_pop" href="#CDR0000062734_rl_12_27">27</a>] It is not currently known what specific patient characteristics are associated with risk for long-term increased fatigue or more severe fatigue and who will experience fatigue resolution.</p></div><div id="CDR0000062734__20"><h3>Anemia</h3><p id="CDR0000062734__21">Evidence suggests that anemia may be a major factor in cancer-related fatigue
|
|
(CRF) and quality of life in cancer patients.[<a class="bk_pop" href="#CDR0000062734_rl_12_28">28</a>-<a class="bk_pop" href="#CDR0000062734_rl_12_30">30</a>] Anemia can be related to the
|
|
disease itself or caused by the therapy. Occasionally, anemia is simply a
|
|
co-occurring medical finding that is related to neither the disease nor the
|
|
therapy. Anemia is often a significant contributor to symptoms in persons with
|
|
cancer. For individual patients, it can be difficult to discern the actual
|
|
impact of anemia because there are often other problems that confound the ability
|
|
to weigh the specific impact of anemia. The impact of anemia varies depending
|
|
on factors such as:[<a class="bk_pop" href="#CDR0000062734_rl_12_31">31</a>]</p><ul id="CDR0000062734__338"><li class="half_rhythm"><div> The rapidity of onset.</div></li><li class="half_rhythm"><div> Patient age.</div></li><li class="half_rhythm"><div>Plasma-volume status.</div></li><li class="half_rhythm"><div> The number and severity of comorbidities.</div></li></ul><p id="CDR0000062734__238">A retrospective review was
|
|
conducted to understand the problem of anemia in patients undergoing radiation
|
|
therapy. Anemia was prevalent in 48% of the patients initially, and increased
|
|
to 57% of the patients during therapy. It was more common in women than men
|
|
(64% vs. 51%); however, men with prostate cancer experienced the greatest
|
|
increase in anemia during radiation therapy.[<a class="bk_pop" href="#CDR0000062734_rl_12_32">32</a>] In certain cancers, such as
|
|
cancer of the cervix and cancer of the head and neck, anemia has been found to
|
|
be a predictor of poor survival and diminished quality of life in patients
|
|
undergoing radiation therapy.[<a class="bk_pop" href="#CDR0000062734_rl_12_33">33</a>-<a class="bk_pop" href="#CDR0000062734_rl_12_36">36</a>]
|
|
</p></div><div id="CDR0000062734__22"><h3>Nutrition Factors</h3><p id="CDR0000062734__23">Fatigue often occurs when the energy requirements of the body exceed the supply
|
|
of energy sources.[<a class="bk_pop" href="#CDR0000062734_rl_12_37">37</a>,<a class="bk_pop" href="#CDR0000062734_rl_12_38">38</a>] In people with cancer, three major mechanisms may be
|
|
involved:</p><ul id="CDR0000062734__339"><li class="half_rhythm"><div>Alteration in the body’s ability to process nutrients efficiently.</div></li><li class="half_rhythm"><div>
|
|
Increase in the body’s energy requirements.</div></li><li class="half_rhythm"><div>Decrease in intake of energy
|
|
sources.</div></li></ul><p id="CDR0000062734__340">Causes of nutritional alterations are listed in <a class="figpopup" href="/books/NBK66049.2/table/CDR0000062734__118/?report=objectonly" target="object" rid-figpopup="figCDR0000062734118" rid-ob="figobCDR0000062734118">Table 1</a>.</p><div id="CDR0000062734__118" class="table"><h3><span class="title">Table 1. Nutrition/Energy Factors</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK66049.2/table/CDR0000062734__118/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__CDR0000062734__118_lrgtbl__"><table class="no_top_margin"><thead><tr><th colspan="1" rowspan="1" style="vertical-align:top;"> Mechanisms </th><th colspan="1" rowspan="1" style="vertical-align:top;">Causes</th></tr></thead><tbody><tr><td colspan="1" rowspan="1" style="vertical-align:top;">Altered ability to process nutrients</td><td colspan="1" rowspan="1" style="vertical-align:top;"> Impaired glucose, lipid, and protein metabolism</td></tr><tr><td colspan="1" rowspan="4" style="vertical-align:top;">Increased energy requirements </td><td colspan="1" rowspan="1" style="vertical-align:top;">Tumor consumption of and
|
|
competition for nutrients</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">Hypermetabolic state due to tumor growth</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">Infection/fever</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;"> Dyspnea</td></tr><tr><td colspan="1" rowspan="4" style="vertical-align:top;">Decreased intake of energy sources</td><td colspan="1" rowspan="1" style="vertical-align:top;">Anorexia</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">Nausea/vomiting</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">Diarrhea</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;"> Bowel obstruction</td></tr></tbody></table></div></div></div><div id="CDR0000062734__26"><h3>Psychologic Factors</h3><p id="CDR0000062734__27">Numerous factors related to the moods, beliefs, attitudes, and reactions to
|
|
stressors of people with cancer can also contribute to the development of
|
|
chronic fatigue. Anxiety and depression are the most common comorbid psychiatric disorders of CRF.[<a class="bk_pop" href="#CDR0000062734_rl_12_39">39</a>] Often, fatigue is the final common pathway for a range of physical and emotional etiologies.
|
|
</p><p id="CDR0000062734__28">Depression can be a comorbid, disabling syndrome that affects approximately 15%
|
|
to 25% of persons with cancer.[<a class="bk_pop" href="#CDR0000062734_rl_12_40">40</a>] The presence of depression, as manifested
|
|
by loss of interest, difficulty concentrating, lethargy, and feelings of
|
|
hopelessness, can compound the physical causes for fatigue in these individuals
|
|
and persist long past the time when physical causes have resolved.[<a class="bk_pop" href="#CDR0000062734_rl_12_41">41</a>]</p><p id="CDR0000062734__341">Anxiety
|
|
and fear associated with a cancer diagnosis, as well as its impact on the
|
|
person’s physical, psychosocial, and financial well-being, are sources of
|
|
emotional stress. Distress associated with the diagnosis of cancer alone may
|
|
trigger fatigue. A study of 74 early-stage breast cancer patients with no
|
|
history of affective disorder assessed various symptoms of adjustment
|
|
approximately 2 weeks after diagnosis; about 45% noted moderate or high levels
|
|
of fatigue. This fatigue may have been secondary to the increased cognitive
|
|
strain of dealing with the diagnosis or to insomnia, reported as moderate to severe by about 60% of the patients. Therefore, fatigue may begin before
|
|
treatment as a result of worry or other cognitive factors, both primary and secondary
|
|
to insomnia. Various forms of treatment may compound this fatigue.[<a class="bk_pop" href="#CDR0000062734_rl_12_42">42</a>]</p><p id="CDR0000062734__342"> In cancer survivors, fatigue may also be increased above levels seen in the general population.[<a class="bk_pop" href="#CDR0000062734_rl_12_43">43</a>,<a class="bk_pop" href="#CDR0000062734_rl_12_44">44</a>] In testicular cancer survivors, anxiety and depression were predictive of fatigue, suggesting a possible role for psychiatric intervention in fatigue management.[<a class="bk_pop" href="#CDR0000062734_rl_12_45">45</a>] (Refer to the PDQ summaries on <a href="/books/n/pdqcis/CDR0000062739/">Depression</a> and <a href="/books/n/pdqcis/CDR0000062891/">Adjustment to Cancer: Anxiety and Distress</a> for
|
|
more information.)</p><p id="CDR0000062734__259">Psychologic and symptom distress have also been found to be significant predictors of fatigue.[<a class="bk_pop" href="#CDR0000062734_rl_12_46">46</a>,<a class="bk_pop" href="#CDR0000062734_rl_12_47">47</a>] In a study of 101 women about to undergo surgery for breast cancer, younger age, presurgery distress, and expectations about fatigue significantly predicted fatigue levels 1 week after surgery. In the regression model, age, distress and expectancy each uniquely contributed to fatigue, with distress and expectancy accounting for 25% of the variance.[<a class="bk_pop" href="#CDR0000062734_rl_12_46">46</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663087/" class="def">Level of evidence: III</a>] In a longitudinal study with women who had gynecologic cancer, symptom and psychologic distress significantly predicted fatigue before, during, and after treatment with chemotherapy, explaining up to 80% of the variance in fatigue scores after chemotherapy treatment.[<a class="bk_pop" href="#CDR0000062734_rl_12_47">47</a>]</p></div><div id="CDR0000062734__29"><h3>Cognitive Factors</h3><p id="CDR0000062734__30">Impairment in cognitive functioning, including decreased attention span and
|
|
impaired perception and thinking, is commonly associated with fatigue.[<a class="bk_pop" href="#CDR0000062734_rl_12_48">48</a>,<a class="bk_pop" href="#CDR0000062734_rl_12_49">49</a>]
|
|
Although fatigue and cognitive impairments are linked, the mechanism underlying
|
|
this association is unclear. Mental demands inherent in the diagnosis and
|
|
treatment of cancer have been well documented, but little is known about the
|
|
concomitant problem of attention fatigue in people with cancer. Attention
|
|
problems are common during and after cancer treatment. Some of the reported
|
|
attention problems may be caused by the fatigue of directed attention.[<a class="bk_pop" href="#CDR0000062734_rl_12_50">50</a>,<a class="bk_pop" href="#CDR0000062734_rl_12_51">51</a>]
|
|
Attention fatigue may be relieved by activities that promote rest and recovery
|
|
of directed attention. Although sleep is necessary for relieving attention
|
|
fatigue and restoring attention, it is insufficient when attention demands are
|
|
high. Empirical literature suggests that the natural environment contains the
|
|
properties for restoring directed attention and relieving attention fatigue.
|
|
</p></div><div id="CDR0000062734__31"><h3>Sleep Disorders and Inactivity</h3><p id="CDR0000062734__343">Causative or contributing factors in CRF may be:</p><ul id="CDR0000062734__344"><li class="half_rhythm"><div>Disrupted sleep.</div></li><li class="half_rhythm"><div>Poor sleep hygiene.</div></li><li class="half_rhythm"><div>Decreased nighttime sleep or excessive daytime sleep.</div></li><li class="half_rhythm"><div>Inactivity.</div></li></ul><p id="CDR0000062734__32">Patients with less daytime activity and more nighttime
|
|
awakenings were noted to consistently report higher levels of CRF. Those with
|
|
lower peak-activity scores, as measured by wristwatch activity monitors,
|
|
experienced higher levels of fatigue.[<a class="bk_pop" href="#CDR0000062734_rl_12_6">6</a>]
|
|
</p><p id="CDR0000062734__260">Sleep disorders clearly contribute to fatigue [<a class="bk_pop" href="#CDR0000062734_rl_12_52">52</a>] and may differentially affect fatigue ratings, depending on the time of the rating. A study that evaluated fatigue in women undergoing radiation therapy for breast cancer found that sleep had a greater influence on morning fatigue values than on evening fatigue scores.[<a class="bk_pop" href="#CDR0000062734_rl_12_16">16</a>] In a similar study of men undergoing radiation therapy for prostate cancer, sleep contributed to both morning and evening fatigue levels.[<a class="bk_pop" href="#CDR0000062734_rl_12_14">14</a>] However, fatigue and sleep can also be distinct problems. One study that resulted in significant improvement in sleep with the use of cognitive behavioral therapy did not significantly affect fatigue.[<a class="bk_pop" href="#CDR0000062734_rl_12_53">53</a>]</p><p id="CDR0000062734__324">Refer to the PDQ summary on <a href="/books/n/pdqcis/CDR0000062746/">Sleep Disorders</a> for more information.</p></div><div id="CDR0000062734__33"><h3>Medications</h3><p id="CDR0000062734__34">Medications other than chemotherapy may contribute to fatigue. Opioids used in the treatment of cancer-related pain are often
|
|
associated with sedation, though the degree of sedation varies among
|
|
individuals. Opioids are known to alter the normal function of the hypothalamic secretion of gonadotropin-releasing hormone.[<a class="bk_pop" href="#CDR0000062734_rl_12_54">54</a>]</p><p id="CDR0000062734__345">Hypogonadism may be found in patients with advanced cancer and can contribute to fatigue during cancer treatment.[<a class="bk_pop" href="#CDR0000062734_rl_12_55">55</a>] One case-control study examined the effects of chronic oral opioid administration in survivors of cancer and, consistent with the research on intrathecal administration, found marked central hypogonadism among the opioid users with significant symptoms of sexual dysfunction, depression, and fatigue.[<a class="bk_pop" href="#CDR0000062734_rl_12_56">56</a>] One trial (<a href="http://cancer.gov/clinicaltrials/search/view?version=healthprofessional&cdrid=653593" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NCT00965341</a>) has studied whether testosterone replacement therapy affects fatigue in men with advanced cancer and low testosterone levels; results are pending.</p><p id="CDR0000062734__230"> Other medications—including tricyclic antidepressants,
|
|
neuroleptics, beta blockers, benzodiazepines, and antihistamines—may produce
|
|
side effects of sedation. In addition, concurrent medications such as analgesics, hypnotics, antidepressants, antiemetics, steroids, or anticonvulsants—many of which act on the central nervous system—can significantly compound the problem of fatigue. The coadministration of multiple drugs with varying
|
|
side effects may compound fatigue symptoms.
|
|
</p></div><div id="CDR0000062734_rl_12"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062734_rl_12_1">Blesch KS, Paice JA, Wickham R, et al.: Correlates of fatigue in people with breast or lung cancer. Oncol Nurs Forum 18 (1): 81-7, 1991 Jan-Feb. [<a href="https://pubmed.ncbi.nlm.nih.gov/2003120" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2003120</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_2">Groopman JE: Fatigue in cancer and HIV/AIDS. Oncology (Huntingt) 12 (3): 335-44; discussion 345-6, 351, 1998. [<a href="https://pubmed.ncbi.nlm.nih.gov/9534184" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9534184</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_3">Irvine DM, Vincent L, Bubela N, et al.: A critical appraisal of the research literature investigating fatigue in the individual with cancer. Cancer Nurs 14 (4): 188-99, 1991. [<a href="https://pubmed.ncbi.nlm.nih.gov/1913633" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1913633</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_4">Hickok JT, Morrow GR, McDonald S, et al.: Frequency and correlates of fatigue in lung cancer patients receiving radiation therapy: implications for management. J Pain Symptom Manage 11 (6): 370-7, 1996. [<a href="https://pubmed.ncbi.nlm.nih.gov/8935141" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8935141</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_5">Von Hoff D: Asthenia: incidence, etiology, pathophysiology, and treatment. Cancer Therapeutics 1: 184-97, 1998.</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_6">Berger AM, Farr L: The influence of daytime inactivity and nighttime restlessness on cancer-related fatigue. Oncol Nurs Forum 26 (10): 1663-71, 1999 Nov-Dec. [<a href="https://pubmed.ncbi.nlm.nih.gov/10573683" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10573683</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_7">Engstrom CA, Strohl RA, Rose L, et al.: Sleep alterations in cancer patients. Cancer Nurs 22 (2): 143-8, 1999. [<a href="https://pubmed.ncbi.nlm.nih.gov/10217030" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10217030</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_8">Dimsdale JE, Ancoli-Israel S, Ayalon L, et al.: Taking fatigue seriously, II: variability in fatigue levels in cancer patients. Psychosomatics 48 (3): 247-52, 2007 May-Jun. [<a href="https://pubmed.ncbi.nlm.nih.gov/17478594" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17478594</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_9">Jacobsen PB, Donovan KA, Small BJ, et al.: Fatigue after treatment for early stage breast cancer: a controlled comparison. Cancer 110 (8): 1851-9, 2007. [<a href="/pmc/articles/PMC2646727/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2646727</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17847016" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17847016</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_10">Collado-Hidalgo A, Bower JE, Ganz PA, et al.: Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res 12 (9): 2759-66, 2006. [<a href="https://pubmed.ncbi.nlm.nih.gov/16675568" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16675568</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_11">Wood LJ, Nail LM, Gilster A, et al.: Cancer chemotherapy-related symptoms: evidence to suggest a role for proinflammatory cytokines. Oncol Nurs Forum 33 (3): 535-42, 2006. [<a href="https://pubmed.ncbi.nlm.nih.gov/16676010" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16676010</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_12">Winningham ML, Nail LM, Burke MB, et al.: Fatigue and the cancer experience: the state of the knowledge. Oncol Nurs Forum 21 (1): 23-36, 1994 Jan-Feb. [<a href="https://pubmed.ncbi.nlm.nih.gov/8139999" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8139999</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_13">Donovan KA, Jacobsen PB, Andrykowski MA, et al.: Course of fatigue in women receiving chemotherapy and/or radiotherapy for early stage breast cancer. J Pain Symptom Manage 28 (4): 373-80, 2004. [<a href="/pmc/articles/PMC2398710/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2398710</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15471655" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15471655</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_14">Miaskowski C, Paul SM, Cooper BA, et al.: Trajectories of fatigue in men with prostate cancer before, during, and after radiation therapy. J Pain Symptom Manage 35 (6): 632-43, 2008. [<a href="/pmc/articles/PMC2491660/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2491660</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18358683" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18358683</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_15">Greenberg DB, Sawicka J, Eisenthal S, et al.: Fatigue syndrome due to localized radiation. J Pain Symptom Manage 7 (1): 38-45, 1992. [<a href="https://pubmed.ncbi.nlm.nih.gov/1538180" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1538180</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_16">Dhruva A, Dodd M, Paul SM, et al.: Trajectories of fatigue in patients with breast cancer before, during, and after radiation therapy. Cancer Nurs 33 (3): 201-12, 2010 May-Jun. [<a href="/pmc/articles/PMC2881569/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2881569</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20357659" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20357659</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_17">Haylock PJ, Hart LK: Fatigue in patients receiving localized radiation. Cancer Nurs 2 (6): 461-7, 1979. [<a href="https://pubmed.ncbi.nlm.nih.gov/259440" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 259440</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_18">King KB, Nail LM, Kreamer K, et al.: Patients' descriptions of the experience of receiving radiation therapy. Oncol Nurs Forum 12 (4): 55-61, 1985 Jul-Aug. [<a href="https://pubmed.ncbi.nlm.nih.gov/3847996" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3847996</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_19">Nail LM: Coping with intracavitary radiation treatment for gynecologic cancer. Cancer Pract 1 (3): 218-24, 1993.</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_20">Larson PJ, Lindsey AM, Dodd MJ, et al.: Influence of age on problems experienced by patients with lung cancer undergoing radiation therapy. Oncol Nurs Forum 20 (3): 473-80, 1993. [<a href="https://pubmed.ncbi.nlm.nih.gov/8497416" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8497416</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_21">Fobair P, Hoppe RT, Bloom J, et al.: Psychosocial problems among survivors of Hodgkin's disease. J Clin Oncol 4 (5): 805-14, 1986. [<a href="https://pubmed.ncbi.nlm.nih.gov/3486256" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3486256</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_22">Piper BF, Rieger PT, Brophy L, et al.: Recent advances in the management of biotherapy-related side effects: fatigue. Oncol Nurs Forum 16 (6 Suppl): 27-34, 1989 Nov-Dec. [<a href="https://pubmed.ncbi.nlm.nih.gov/2480583" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2480583</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_23">Haeuber D: Recent advances in the management of biotherapy-related side effects: flu-like syndrome. Oncol Nurs Forum 16 (6 Suppl): 35-41, 1989 Nov-Dec. [<a href="https://pubmed.ncbi.nlm.nih.gov/2687812" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2687812</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_24">Mattson K, Niiranen A, Iivanainen M, et al.: Neurotoxicity of interferon. Cancer Treat Rep 67 (10): 958-61, 1983. [<a href="https://pubmed.ncbi.nlm.nih.gov/6194882" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6194882</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_25">Berger AM, Lockhart K, Agrawal S: Variability of patterns of fatigue and quality of life over time based on different breast cancer adjuvant chemotherapy regimens. Oncol Nurs Forum 36 (5): 563-70, 2009. [<a href="https://pubmed.ncbi.nlm.nih.gov/19726396" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19726396</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_26">So WK, Marsh G, Ling WM, et al.: The symptom cluster of fatigue, pain, anxiety, and depression and the effect on the quality of life of women receiving treatment for breast cancer: a multicenter study. Oncol Nurs Forum 36 (4): E205-14, 2009. [<a href="https://pubmed.ncbi.nlm.nih.gov/19581224" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19581224</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_27">Goedendorp MM, Andrykowski MA, Donovan KA, et al.: Prolonged impact of chemotherapy on fatigue in breast cancer survivors: a longitudinal comparison with radiotherapy-treated breast cancer survivors and noncancer controls. Cancer 118 (15): 3833-41, 2012. [<a href="/pmc/articles/PMC4007757/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC4007757</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22086766" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22086766</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_28">Glaspy J, Bukowski R, Steinberg D, et al.: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 15 (3): 1218-34, 1997. [<a href="https://pubmed.ncbi.nlm.nih.gov/9060566" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9060566</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_29">Vogelzang NJ, Breitbart W, Cella D, et al.: Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 34 (3 Suppl 2): 4-12, 1997. [<a href="https://pubmed.ncbi.nlm.nih.gov/9253778" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9253778</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_30">Demetri GD, Kris M, Wade J, et al.: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16 (10): 3412-25, 1998. [<a href="https://pubmed.ncbi.nlm.nih.gov/9779721" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9779721</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_31">Johnston E, Crawford J: The hematologic support of the cancer patient. In: Berger A, Portenoy RK, Weissman DE, eds.: Principles and Practice of Supportive Oncology. Philadelphia, Pa: Lippincott-Raven Publishers, 1998, pp 549-69.</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_32">Bush RS: The significance of anemia in clinical radiation therapy. Int J Radiat Oncol Biol Phys 12 (11): 2047-50, 1986. [<a href="https://pubmed.ncbi.nlm.nih.gov/3771322" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3771322</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_33">Fein DA, Lee WR, Hanlon AL, et al.: Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 13 (8): 2077-83, 1995. [<a href="https://pubmed.ncbi.nlm.nih.gov/7636551" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7636551</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_34">Girinski T, Pejovic-Lenfant MH, Bourhis J, et al.: Prognostic value of hemoglobin concentrations and blood transfusions in advanced carcinoma of the cervix treated by radiation therapy: results of a retrospective study of 386 patients. Int J Radiat Oncol Biol Phys 16 (1): 37-42, 1989. [<a href="https://pubmed.ncbi.nlm.nih.gov/2912956" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2912956</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_35">Dubray B, Mosseri V, Brunin F, et al.: Anemia is associated with lower local-regional control and survival after radiation therapy for head and neck cancer: a prospective study. Radiology 201 (2): 553-8, 1996. [<a href="https://pubmed.ncbi.nlm.nih.gov/8888257" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8888257</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_36">Dunst J: Hemoglobin level and anemia in radiation oncology: prognostic impact and therapeutic implications. Semin Oncol 27 (2 Suppl 4): 4-8; discussion 16-7, 2000. [<a href="https://pubmed.ncbi.nlm.nih.gov/10847301" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10847301</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_37">Watanabe S, Bruera E: Anorexia and cachexia, asthenia, and lethargy. Hematol Oncol Clin North Am 10 (1): 189-206, 1996. [<a href="https://pubmed.ncbi.nlm.nih.gov/8821567" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8821567</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_38">MacDonald N, Alexander HR, Bruera E: Cachexia-anorexia-asthenia. J Pain Symptom Manage 10 (2): 151-5, 1995. [<a href="https://pubmed.ncbi.nlm.nih.gov/7730686" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7730686</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_39">Reich SG: The tired patient: psychological versus organic causes. Hosp Med 22 (7): 142-54, 1986.</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_40">Henriksson MM, Isometsä ET, Hietanen PS, et al.: Mental disorders in cancer suicides. J Affect Disord 36 (1-2): 11-20, 1995. [<a href="https://pubmed.ncbi.nlm.nih.gov/8988260" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8988260</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_41">Cella D, Davis K, Breitbart W, et al.: Cancer-related fatigue: prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 19 (14): 3385-91, 2001. [<a href="https://pubmed.ncbi.nlm.nih.gov/11454886" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11454886</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_42">Cimprich B: Pretreatment symptom distress in women newly diagnosed with breast cancer. Cancer Nurs 22 (3): 185-94; quiz 195, 1999. [<a href="https://pubmed.ncbi.nlm.nih.gov/10376379" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10376379</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_43">Sugawara Y, Akechi T, Okuyama T, et al.: Occurrence of fatigue and associated factors in disease-free breast cancer patients without depression. Support Care Cancer 13 (8): 628-36, 2005. [<a href="https://pubmed.ncbi.nlm.nih.gov/15668753" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15668753</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_44">Bower JE, Ganz PA, Desmond KA, et al.: Fatigue in long-term breast carcinoma survivors: a longitudinal investigation. Cancer 106 (4): 751-8, 2006. [<a href="https://pubmed.ncbi.nlm.nih.gov/16400678" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16400678</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_45">Fosså SD, Dahl AA, Loge JH: Fatigue, anxiety, and depression in long-term survivors of testicular cancer. J Clin Oncol 21 (7): 1249-54, 2003. [<a href="https://pubmed.ncbi.nlm.nih.gov/12663711" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12663711</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_46">Montgomery GH, Schnur JB, Erblich J, et al.: Presurgery psychological factors predict pain, nausea, and fatigue one week after breast cancer surgery. J Pain Symptom Manage 39 (6): 1043-52, 2010. [<a href="/pmc/articles/PMC2918882/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2918882</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20538186" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20538186</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_47">Prue G, Allen J, Gracey J, et al.: Fatigue in gynecological cancer patients during and after anticancer treatment. J Pain Symptom Manage 39 (2): 197-210, 2010. [<a href="https://pubmed.ncbi.nlm.nih.gov/19995675" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19995675</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_48">Rhodes VA, Watson PM, Hanson BM: Patients' descriptions of the influence of tiredness and weakness on self-care abilities. Cancer Nurs 11 (3): 186-94, 1988. [<a href="https://pubmed.ncbi.nlm.nih.gov/3401854" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3401854</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_49">Fan HG, Houédé-Tchen N, Yi QL, et al.: Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol 23 (31): 8025-32, 2005. [<a href="https://pubmed.ncbi.nlm.nih.gov/16258100" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16258100</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_50">Holmes S: Preliminary investigations of symptom distress in two cancer patient populations: evaluation of a measurement instrument. J Adv Nurs 16 (4): 439-46, 1991. [<a href="https://pubmed.ncbi.nlm.nih.gov/2061507" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2061507</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_51">Oberst MT, James RH: Going home: patient and spouse adjustment following cancer surgery. Top Clin Nurs 7 (1): 46-57, 1985. [<a href="https://pubmed.ncbi.nlm.nih.gov/3844889" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3844889</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_52">Ancoli-Israel S, Liu L, Marler MR, et al.: Fatigue, sleep, and circadian rhythms prior to chemotherapy for breast cancer. Support Care Cancer 14 (3): 201-9, 2006. [<a href="/pmc/articles/PMC1599708/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1599708</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16010529" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16010529</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_53">Berger AM, Kuhn BR, Farr LA, et al.: One-year outcomes of a behavioral therapy intervention trial on sleep quality and cancer-related fatigue. J Clin Oncol 27 (35): 6033-40, 2009. [<a href="/pmc/articles/PMC2793045/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2793045</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19884558" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19884558</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_54">Katz N, Mazer NA: The impact of opioids on the endocrine system. Clin J Pain 25 (2): 170-5, 2009. [<a href="https://pubmed.ncbi.nlm.nih.gov/19333165" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19333165</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_55">Strasser F, Palmer JL, Schover LR, et al.: The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer: a pilot study. Cancer 107 (12): 2949-57, 2006. [<a href="https://pubmed.ncbi.nlm.nih.gov/17103445" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17103445</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_12_56">Rajagopal A, Vassilopoulou-Sellin R, Palmer JL, et al.: Symptomatic hypogonadism in male survivors of cancer with chronic exposure to opioids. Cancer 100 (4): 851-8, 2004. [<a href="https://pubmed.ncbi.nlm.nih.gov/14770444" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14770444</span></a>]</div></li></ol></div></div><div id="CDR0000062734__35"><h2 id="_CDR0000062734__35_">Assessment</h2><p id="CDR0000062734__36">Assessment of fatigue is multidimensional in nature,[<a class="bk_pop" href="#CDR0000062734_rl_35_1">1</a>] and a number of tools originally developed for fatigue research have also been used in clinical practice. Most of these tools include symptom dimensions other than fatigue intensity, such as the impact or consequences of fatigue, timing of fatigue, related symptoms, and self-care actions.[<a class="bk_pop" href="#CDR0000062734_rl_35_2">2</a>-<a class="bk_pop" href="#CDR0000062734_rl_35_10">10</a>] Research has also contributed a validated 10-item measure for children.[<a class="bk_pop" href="#CDR0000062734_rl_35_11">11</a>]
|
|
</p><p id="CDR0000062734__270">However, much of the time in clinical practice, because of perceived provider/patient burden, screening most often relies on a single-item fatigue intensity rating.[<a class="bk_pop" href="#CDR0000062734_rl_35_12">12</a>-<a class="bk_pop" href="#CDR0000062734_rl_35_15">15</a>] According to National Comprehensive Cancer Network (NCCN) guidelines, ratings of fatigue of 4 or higher on a scale of 0 to 10 (where 10 is very severe fatigue) are further evaluated for known contributing factors such as pain, emotional distress, anemia, sleep, nutrition, and level of activity. These comorbidities are then treated.[<a class="bk_pop" href="#CDR0000062734_rl_35_16">16</a>] One study of ambulatory outpatients with solid tumors (N = 148) evaluated the usefulness of single-item screening for symptoms such as fatigue and pain.[<a class="bk_pop" href="#CDR0000062734_rl_35_12">12</a>] Investigators found that the single-item assessment can assist as a first screening step to identify patients requiring comprehensive assessment of symptoms. Patients identified by using single-item screening tools undergo comprehensive assessments to detect clinically relevant symptomatology.[<a class="bk_pop" href="#CDR0000062734_rl_35_12">12</a>,<a class="bk_pop" href="#CDR0000062734_rl_35_13">13</a>]</p><div id="CDR0000062734__277"><h3>Multiple-Item Tools</h3><p id="CDR0000062734__278">Ambiguous literature
|
|
and a previous lack of specific tools to measure fatigue have created
|
|
difficulties in establishing assessment and management guidelines.
|
|
Comprehensive assessment of the fatigued patient starts with obtaining a
|
|
careful history to characterize the individual’s fatigue pattern and to
|
|
identify all factors that contribute to its development. The following may
|
|
be included in the initial assessment:</p><ul id="CDR0000062734__279"><li class="half_rhythm"><div>Self-report of fatigue pattern, including onset, duration, intensity, and aggravating and alleviating factors.</div></li><li class="half_rhythm"><div>Type and degree of disease- and of treatment-related symptoms and/or side
|
|
effects.
|
|
</div></li><li class="half_rhythm"><div>Treatment history.</div></li><li class="half_rhythm"><div>Current medications.</div></li><li class="half_rhythm"><div>Sleep and/or rest patterns, relaxation habits, customs, and rituals.</div></li><li class="half_rhythm"><div>Nutrition intake and any appetite or weight changes.</div></li><li class="half_rhythm"><div>Effects of fatigue on activities of daily living and lifestyle.</div></li><li class="half_rhythm"><div>Psychiatric evaluation, including evaluation for depression.
|
|
</div></li><li class="half_rhythm"><div>Complete physical examination, including gait, posture, and range of
|
|
motion.</div></li><li class="half_rhythm"><div>Compliance with treatment.</div></li><li class="half_rhythm"><div>Job performance.</div></li><li class="half_rhythm"><div>Financial resources.</div></li><li class="half_rhythm"><div>Other contributing factors (e.g., anemia, dyspnea, muscle wasting).</div></li></ul><p id="CDR0000062734__280">Specific attention is paid to underlying factors that contribute to
|
|
fatigue and may be correctable, including the following:[<a class="bk_pop" href="#CDR0000062734_rl_35_17">17</a>,<a class="bk_pop" href="#CDR0000062734_rl_35_18">18</a>]</p><ul id="CDR0000062734__296"><li class="half_rhythm"><div>Anemia.</div></li><li class="half_rhythm"><div>Depression.</div></li><li class="half_rhythm"><div>Anxiety.</div></li><li class="half_rhythm"><div>Pain.</div></li><li class="half_rhythm"><div>Dehydration.</div></li><li class="half_rhythm"><div>Nutritional deficiencies (e.g., protein, calories,
|
|
vitamins).</div></li><li class="half_rhythm"><div>Sedating medications (e.g., opioids, benzodiazepines).</div></li><li class="half_rhythm"><div>Neurotoxic
|
|
therapies.</div></li><li class="half_rhythm"><div>Infection.</div></li><li class="half_rhythm"><div>Fever.</div></li><li class="half_rhythm"><div>Sleep disturbances.</div></li><li class="half_rhythm"><div>Immobility.</div></li></ul><p id="CDR0000062734__281">Proposed criteria for cancer-related fatigue (CRF) are listed <a href="#CDR0000062734__282">below</a>. These
|
|
criteria have been adopted for inclusion in the <i>International Statistical Classification of
|
|
Diseases and Related Health Problems, Tenth Revision, Clinical Modification</i> (ICD-10-CM).[<a class="bk_pop" href="#CDR0000062734_rl_35_19">19</a>]</p><p id="CDR0000062734__297">Defining
|
|
CRF as a diagnostic syndrome has some potential advantages
|
|
and disadvantages.[<a class="bk_pop" href="#CDR0000062734_rl_35_20">20</a>] One of the possible advantages is that it would enable
|
|
clinicians to document the presence or absence of fatigue in a reproducible
|
|
fashion. It may also be useful in establishing appropriate reimbursement for
|
|
management of this finding. The potential disadvantage of this approach is
|
|
that it may deter management of fatigue that does not reach the threshold for
|
|
ICD-10 diagnosis. The alternative to the syndrome-based approach (commonly used for depression) is a
|
|
symptom-based approach, which is commonly used for
|
|
phenomena such as pain and nausea. The utility of the following ICD-10 criteria for CRF has not been validated.</p><p id="CDR0000062734__282"><b>ICD-10 Criteria for Cancer-related Fatigue</b></p><p id="CDR0000062734__283">The following symptoms have been present every day or nearly every day during
|
|
the same 2-week period in the past month:</p><ol id="CDR0000062734__284" class="upper-alpha"><li class="half_rhythm"><div>Significant fatigue, diminished energy, or increased need to rest,
|
|
disproportionate to any recent change in activity level, plus five or more of the
|
|
following:<ol id="CDR0000062734__285"><li class="half_rhythm"><div>Complaints of generalized weakness, limb heaviness.</div></li><li class="half_rhythm"><div>Diminished concentration or attention.</div></li><li class="half_rhythm"><div>Decreased motivation or interest to engage in usual activities.</div></li><li class="half_rhythm"><div>Insomnia or hypersomnia.</div></li><li class="half_rhythm"><div>Experience of sleep as unrefreshing or nonrestorative.</div></li><li class="half_rhythm"><div>Perceived need to struggle to overcome inactivity.</div></li><li class="half_rhythm"><div>Marked emotional reactivity (e.g., sadness, frustration, or irritability)
|
|
to feeling fatigued.</div></li><li class="half_rhythm"><div>Difficulty completing daily tasks attributed to feeling fatigued.</div></li><li class="half_rhythm"><div>Perceived problems with short-term memory.</div></li><li class="half_rhythm"><div>Postexertional fatigue lasting several hours.</div></li></ol></div></li><li class="half_rhythm"><div>The symptoms cause clinically significant distress or impairment in social,
|
|
occupational, or other important areas of functioning.</div></li><li class="half_rhythm"><div>There is evidence from the history, physical examination, or laboratory
|
|
findings that the symptoms are a consequence of cancer or cancer therapy.</div></li><li class="half_rhythm"><div>The symptoms are not primarily a consequence of comorbid psychiatric
|
|
disorders such as major depression, somatization disorder, somatoform disorder,
|
|
or delirium.</div></li></ol><p id="CDR0000062734__286">As with other self-reported symptoms such as pain, it may be necessary to
|
|
encourage the patient and other family members to report symptoms of fatigue to
|
|
the medical staff. Information regarding the potential for fatigue due to the
|
|
underlying disease or treatments, possible options for management, and the
|
|
importance of reporting these symptoms is given to patients at the
|
|
initiation of treatment.[<a class="bk_pop" href="#CDR0000062734_rl_35_17">17</a>] Patients may not mention the fatigue they
|
|
experience unless they are prompted by a health professional.</p><p id="CDR0000062734__298">Several barriers hamper appropriate management of CRF. Some of these barriers were identified in phase 1 of an ongoing three-phase project related to the implementation of evidence-based (NCCN) guidelines for fatigue management.[<a class="bk_pop" href="#CDR0000062734_rl_35_21">21</a>] The most commonly identified barriers were the following:[<a class="bk_pop" href="#CDR0000062734_rl_35_21">21</a>,<a class="bk_pop" href="#CDR0000062734_rl_35_22">22</a>]</p><ul id="CDR0000062734__299"><li class="half_rhythm"><div>Patient’s belief that the physician would introduce the subject of fatigue if it was important (patient barrier).</div></li><li class="half_rhythm"><div>Lack of fatigue documentation (professional barrier).</div></li><li class="half_rhythm"><div>Lack of supportive care referrals (system barrier).</div></li></ul><p id="CDR0000062734__287">Although there is no universally accepted standard for the measurement of
|
|
fatigue, there are a variety of instruments that have been developed to assess
|
|
fatigue and related sequelae.[<a class="bk_pop" href="#CDR0000062734_rl_35_2">2</a>-<a class="bk_pop" href="#CDR0000062734_rl_35_6">6</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663072/" class="def">Level of evidence: II</a>];[<a class="bk_pop" href="#CDR0000062734_rl_35_7">7</a>-<a class="bk_pop" href="#CDR0000062734_rl_35_10">10</a>] Fatigue is also commonly assessed in multidimensional quality-of-life instruments. Selected instruments for assessing fatigue are listed
|
|
below.</p><ul id="CDR0000062734__288"><li class="half_rhythm"><div>Brief Fatigue Inventory.[<a class="bk_pop" href="#CDR0000062734_rl_35_4">4</a>]</div></li><li class="half_rhythm"><div>The Functional Assessment of Cancer Therapy-Anemia.[<a class="bk_pop" href="#CDR0000062734_rl_35_7">7</a>]</div></li><li class="half_rhythm"><div>The Functional Assessment of Cancer Therapy-Fatigue.[<a class="bk_pop" href="#CDR0000062734_rl_35_8">8</a>]</div></li><li class="half_rhythm"><div>The Piper Fatigue Scale (long and short versions).[<a class="bk_pop" href="#CDR0000062734_rl_35_3">3</a>,<a class="bk_pop" href="#CDR0000062734_rl_35_23">23</a>]</div></li><li class="half_rhythm"><div>The Schwartz Cancer Fatigue Scale.[<a class="bk_pop" href="#CDR0000062734_rl_35_9">9</a>]</div></li><li class="half_rhythm"><div>Fatigue Symptom Inventory.[<a class="bk_pop" href="#CDR0000062734_rl_35_6">6</a>]</div></li><li class="half_rhythm"><div>The Profile of Mood States Fatigue/Inertia Subscale.[<a class="bk_pop" href="#CDR0000062734_rl_35_10">10</a>]</div></li><li class="half_rhythm"><div>Lee’s Visual Analogue Scale for Fatigue.[<a class="bk_pop" href="#CDR0000062734_rl_35_2">2</a>]</div></li><li class="half_rhythm"><div>Cancer Fatigue Scale.[<a class="bk_pop" href="#CDR0000062734_rl_35_5">5</a>]</div></li><li class="half_rhythm"><div>Multidimensional Fatigue Symptom Inventory-Short Form.[<a class="bk_pop" href="#CDR0000062734_rl_35_24">24</a>]</div></li></ul></div><div id="CDR0000062734__78"><h3>Evaluation of Anemia</h3><p id="CDR0000062734__79">The proper evaluation of anemia in cancer patients includes the following:</p><ul id="CDR0000062734__346"><li class="half_rhythm"><div>A careful history
|
|
and physical examination.</div></li><li class="half_rhythm"><div>An evaluation of the complete blood count and red
|
|
blood cell indices.</div></li><li class="half_rhythm"><div>An examination of the peripheral blood smear.</div></li></ul><p id="CDR0000062734__347"> In
|
|
combination, the information from these investigations is often diagnostic.</p><p id="CDR0000062734__80">One commonly used method for classifying anemia is to categorize the anemia by
|
|
the size of the red blood cell as measured by the mean corpuscular volume
|
|
(MCV). Microcytic anemias are associated with an MCV of 79
|
|
fL or lower and include iron-deficiency anemia, thalassemia, and anemia of
|
|
chronic disease. Macrocytic anemias are associated with an MCV higher than 101 fL and include anemias related to vitamin B<sub>12</sub> or folate
|
|
deficiency, myelodysplasia, and liver disease. Most anemias are normocytic,
|
|
meaning that the MCV is in the normal range. This category includes
|
|
the following:[<a class="bk_pop" href="#CDR0000062734_rl_35_25">25</a>]</p><ul id="CDR0000062734__300"><li class="half_rhythm"><div>Myelophthisic anemia (i.e., anemia due to neoplastic replacement of the bone marrow).</div></li><li class="half_rhythm"><div>Most chemotherapy-related anemias.</div></li><li class="half_rhythm"><div>Anemia due to renal or hepatic dysfunction.</div></li><li class="half_rhythm"><div>Hemolytic anemia.</div></li><li class="half_rhythm"><div>Aplastic anemia.</div></li></ul><p id="CDR0000062734__301">However, a mixed red blood cell population
|
|
consisting of both microcytic and macrocytic cells (anisocytosis) may
|
|
indicate a combined etiology, for example, chronic blood loss (microcytic) with
|
|
resultant reticulocytosis (macrocytic). In this situation, the MCV may be in
|
|
the normal range, but the red blood cell size distribution width would be
|
|
elevated.</p><p id="CDR0000062734__81">The peripheral blood smear examination, though often overlooked, remains an
|
|
important step in the evaluation of anemia. For example, nucleated blood cells
|
|
and teardrop-shaped red blood cells suggest myelophthisic anemia.
|
|
Macro-ovalocytes and hypersegmented neutrophils often indicate megaloblastic
|
|
anemia. Small target cells and basophilic stippling are associated with
|
|
thalassemia.</p><p id="CDR0000062734__82">Additional studies that are sometimes required to characterize anemia in a
|
|
given patient include testing of vitamin B<sub>12</sub> or folate levels; serum iron,
|
|
transferrin, and ferritin levels; erythropoietin level, the direct and indirect
|
|
Coombs test, and/or examination of a bone marrow aspirate and biopsy. In
|
|
cancer patients, the underlying etiology is often multifactorial.</p></div><div id="CDR0000062734_rl_35"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062734_rl_35_1">Portenoy RK, Miaskowski C: Assessment and management of cancer-related fatigue. In: Berger A, Portenoy RK, Weissman DE, eds.: Principles and Practice of Supportive Oncology. Philadelphia, Pa: Lippincott-Raven Publishers, 1998, pp 109-18.</div></li><li><div class="bk_ref" id="CDR0000062734_rl_35_2">Lee KA, Hicks G, Nino-Murcia G: Validity and reliability of a scale to assess fatigue. Psychiatry Res 36 (3): 291-8, 1991. [<a href="https://pubmed.ncbi.nlm.nih.gov/2062970" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2062970</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_35_3">Piper BF, Dibble SL, Dodd MJ, et al.: The revised Piper Fatigue Scale: psychometric evaluation in women with breast cancer. Oncol Nurs Forum 25 (4): 677-84, 1998. [<a href="https://pubmed.ncbi.nlm.nih.gov/9599351" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9599351</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_35_4">Mendoza TR, Wang XS, Cleeland CS, et al.: The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 85 (5): 1186-96, 1999. [<a href="https://pubmed.ncbi.nlm.nih.gov/10091805" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10091805</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_35_5">Okuyama T, Akechi T, Kugaya A, et al.: Development and validation of the cancer fatigue scale: a brief, three-dimensional, self-rating scale for assessment of fatigue in cancer patients. J Pain Symptom Manage 19 (1): 5-14, 2000. [<a href="https://pubmed.ncbi.nlm.nih.gov/10687321" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10687321</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_35_6">Hann DM, Denniston MM, Baker F: Measurement of fatigue in cancer patients: further validation of the Fatigue Symptom Inventory. Qual Life Res 9 (7): 847-54, 2000. [<a href="https://pubmed.ncbi.nlm.nih.gov/11297027" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11297027</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_35_7">Cella D: The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 34 (3 Suppl 2): 13-9, 1997. [<a href="https://pubmed.ncbi.nlm.nih.gov/9253779" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9253779</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_35_8">Cella D: Manual of the Functional Assessment of Chronic Illness Therapy (FACIT) Scales. Version 4. Evanston, Ill: Evanston Northwestern Healthcare, 1997.</div></li><li><div class="bk_ref" id="CDR0000062734_rl_35_9">Schwartz AL: The Schwartz Cancer Fatigue Scale: testing reliability and validity. Oncol Nurs Forum 25 (4): 711-7, 1998. [<a href="https://pubmed.ncbi.nlm.nih.gov/9599354" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9599354</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_35_10">McNair D, Lorr M, Droppelman L, et al.: Profile of Mood States. San Diego, Calif: Educational and Industrial Testing Service, 1971.</div></li><li><div class="bk_ref" id="CDR0000062734_rl_35_11">Hinds PS, Yang J, Gattuso JS, et al.: Psychometric and clinical assessment of the 10-item reduced version of the Fatigue Scale-Child instrument. J Pain Symptom Manage 39 (3): 572-8, 2010. [<a href="/pmc/articles/PMC2941159/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2941159</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20303031" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20303031</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_35_12">Butt Z, Wagner LI, Beaumont JL, et al.: Use of a single-item screening tool to detect clinically significant fatigue, pain, distress, and anorexia in ambulatory cancer practice. J Pain Symptom Manage 35 (1): 20-30, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/17959345" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17959345</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_35_13">Kirsh KL, Passik S, Holtsclaw E, et al.: I get tired for no reason: a single item screening for cancer-related fatigue. J Pain Symptom Manage 22 (5): 931-7, 2001. [<a href="https://pubmed.ncbi.nlm.nih.gov/11728796" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11728796</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_35_14">Strasser F, Müller-Käser I, Dietrich D: Evaluating cognitive, emotional, and physical fatigue domains in daily practice by single-item questions in patients with advanced cancer: a cross-sectional pragmatic study. J Pain Symptom Manage 38 (4): 505-14, 2009. [<a href="https://pubmed.ncbi.nlm.nih.gov/19822275" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19822275</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_35_15">Temel JS, Pirl WF, Recklitis CJ, et al.: Feasibility and validity of a one-item fatigue screen in a thoracic oncology clinic. J Thorac Oncol 1 (5): 454-9, 2006. [<a href="https://pubmed.ncbi.nlm.nih.gov/17409899" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17409899</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_35_16">Berger AM, Abernethy AP, Atkinson A, et al.: Cancer-related fatigue. J Natl Compr Canc Netw 8 (8): 904-31, 2010. [<a href="https://pubmed.ncbi.nlm.nih.gov/20870636" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20870636</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_35_17">Cella D, Peterman A, Passik S, et al.: Progress toward guidelines for the management of fatigue. Oncology (Huntingt) 12 (11A): 369-77, 1998. [<a href="https://pubmed.ncbi.nlm.nih.gov/10028520" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10028520</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_35_18">Groopman JE: Fatigue in cancer and HIV/AIDS. Oncology (Huntingt) 12 (3): 335-44; discussion 345-6, 351, 1998. [<a href="https://pubmed.ncbi.nlm.nih.gov/9534184" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9534184</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_35_19">Portenoy RK, Itri LM: Cancer-related fatigue: guidelines for evaluation and management. Oncologist 4 (1): 1-10, 1999. [<a href="https://pubmed.ncbi.nlm.nih.gov/10337366" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10337366</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_35_20">Sadler IJ, Jacobsen PB, Booth-Jones M, et al.: Preliminary evaluation of a clinical syndrome approach to assessing cancer-related fatigue. J Pain Symptom Manage 23 (5): 406-16, 2002. [<a href="https://pubmed.ncbi.nlm.nih.gov/12007758" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12007758</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_35_21">Borneman T, Piper BF, Sun VC, et al.: Implementing the Fatigue Guidelines at one NCCN member institution: process and outcomes. J Natl Compr Canc Netw 5 (10): 1092-101, 2007. [<a href="/pmc/articles/PMC2515169/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2515169</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18053431" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18053431</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_35_22">Passik SD, Kirsh KL, Donaghy K, et al.: Patient-related barriers to fatigue communication: initial validation of the fatigue management barriers questionnaire. J Pain Symptom Manage 24 (5): 481-93, 2002. [<a href="https://pubmed.ncbi.nlm.nih.gov/12547048" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12547048</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_35_23">Reeve BB, Stover AM, Alfano CM, et al.: The Piper Fatigue Scale-12 (PFS-12): psychometric findings and item reduction in a cohort of breast cancer survivors. Breast Cancer Res Treat 136 (1): 9-20, 2012. [<a href="/pmc/articles/PMC3739964/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3739964</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22933027" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22933027</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_35_24">Stein KD, Jacobsen PB, Blanchard CM, et al.: Further validation of the multidimensional fatigue symptom inventory-short form. J Pain Symptom Manage 27 (1): 14-23, 2004. [<a href="/pmc/articles/PMC2547485/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2547485</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14711465" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14711465</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_35_25">Armitage JO: Management of anemia in patients with cancer. Clinical Oncology Updates 1: 1-12, 1998.</div></li></ol></div></div><div id="CDR0000062734__83"><h2 id="_CDR0000062734__83_">Intervention</h2><p id="CDR0000062734__84">Much of the information regarding interventions for fatigue relates either to
|
|
healthy subjects or to persons in whom muscle fatigue is the primary etiology of
|
|
the problem or fatigue is secondary to treatment-related anemia.[<a class="bk_pop" href="#CDR0000062734_rl_83_1">1</a>,<a class="bk_pop" href="#CDR0000062734_rl_83_2">2</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663072/" class="def">Level of evidence: II</a>];[<a class="bk_pop" href="#CDR0000062734_rl_83_3">3</a>,<a class="bk_pop" href="#CDR0000062734_rl_83_4">4</a>] Without
|
|
a determination of the causative mechanisms of fatigue in oncology patients,
|
|
interventions must be directed to symptom management and emotional support.
|
|
Although some recommendations for the management of fatigue in oncology
|
|
patients have been made, these are theoretical or anecdotal in nature and in
|
|
general have not been the focus of scientific evaluation.
|
|
</p><p id="CDR0000062734__355">Published in 2013, a study conducted in patients with advanced cancer (N = 152) demonstrated that managing symptoms (e.g., pain, nausea, and decreased appetite) can have a significant positive impact on fatigue. In this 12-week study, patients were randomly assigned to receive either monitoring and protocolized treatment of physical symptoms coordinated by a nurse or care as usual (symptom management included in the standard oncologic care). Patients in the intervention group received tailored treatment for any of the identified troublesome symptoms. Fatigue levels, as measured by the Multidimensional Fatigue Inventory, showed significant improvement in the intervention group compared with the group receiving care as usual. The intervention group also showed improvements in the following:[<a class="bk_pop" href="#CDR0000062734_rl_83_5">5</a>] </p><ul id="CDR0000062734__364"><li class="half_rhythm"><div>Specific fatigue dimensions.</div></li><li class="half_rhythm"><div>Interference by fatigue with daily life.</div></li><li class="half_rhythm"><div>Overall symptom burden.</div></li><li class="half_rhythm"><div>Symptoms of depression and anxiety.</div></li></ul><p id="CDR0000062734__365">Similar studies are needed to investigate whether treatment of specific physical and psychological symptoms can alleviate fatigue and to identify patient populations that might benefit from such management. One message of this study may be that fatigue can be a primary symptom or a secondary symptom (a result of other bothersome problems). Therefore, assessing patients for the appropriate target symptom for intervention is probably the most efficient way to help patients improve health-related quality of life.</p><p id="CDR0000062734__85">Because the etiology and mechanisms regarding fatigue/asthenia in cancer patients
|
|
are indeterminate, there is considerable variation in practice patterns
|
|
regarding the management of this symptom. The focus of medical management is
|
|
often directed at identifying specific and potentially reversible correlated
|
|
symptoms, as in the following examples:</p><ul id="CDR0000062734__302"><li class="half_rhythm"><div> Patients with fatigue and pain may have titration of
|
|
pain medications.</div></li><li class="half_rhythm"><div>Patients with fatigue and anemia may receive a transfusion of
|
|
packed red blood cells, nutritional interventions including iron-rich foods,
|
|
supplemental iron or vitamins to correct an underlying deficiency, or
|
|
injections of epoetin alfa.</div></li><li class="half_rhythm"><div>Patients with depressed mood and fatigue may be
|
|
treated with antidepressants or psychostimulants.</div></li></ul><p id="CDR0000062734__303">It is often helpful to
|
|
consider discontinuation of drugs that may be safely withheld. There is no
|
|
agreed-upon approach for the evaluation and treatment of fatigue, but an increasing number of clinical trials are designed to address this issue
|
|
in cancer patients.</p><div id="CDR0000062734__380"><h3>Treatment of Anemia</h3><p id="CDR0000062734__381">Anemia in patients with cancer is best managed by treatment of the underlying cause. When the cause is obscure or there is no specific remedy, then treatment is supportive. Nutritional interventions, including the intake of nutrient-rich foods and supplements, are considered in addition to other treatment modalities. Transfusion of packed red blood cells is the most widely used and most rapid way to alleviate symptoms in cancer patients with symptomatic anemia. The likelihood of success in raising the level of hemoglobin is very high with transfusion, and the risks of complications are low. Nevertheless, repeated transfusions can be cumbersome, and the risks of blood-borne infection can be worrisome for patients. Other risks include an acute transfusion reaction, transfusion-associated graft-versus-host disease, subtle immune modulation that occurs with transfusion, and iron overload in patients who receive repeated transfusions.[<a class="bk_pop" href="#CDR0000062734_rl_83_6">6</a>]</p><p id="CDR0000062734__382">Several large, community-based studies have examined the effectiveness of epoetin alfa and darbepoetin alfa [<a class="bk_pop" href="#CDR0000062734_rl_83_7">7</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663069/" class="def">Level of evidence: I</a>];[<a class="bk_pop" href="#CDR0000062734_rl_83_8">8</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663069/" class="def">Level of evidence: I</a>] in the treatment of cancer-related anemia in patients receiving chemotherapy.[<a class="bk_pop" href="#CDR0000062734_rl_83_2">2</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663072/" class="def">Level of evidence: II</a>];[<a class="bk_pop" href="#CDR0000062734_rl_83_9">9</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663087/" class="def">Level of evidence: III</a>];[<a class="bk_pop" href="#CDR0000062734_rl_83_10">10</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663069/" class="def">Level of evidence: I</a>] A few of the studies of epoetin alfa employed an open-label, nonrandomized design
|
|
and included objective endpoints (hemoglobin response, transfusion
|
|
requirements) and subjective evaluation of fatigue and quality of life. In
|
|
this setting, epoetin alfa has been effective at increasing hemoglobin levels
|
|
and decreasing transfusion requirements. In addition, epoetin alfa has been
|
|
associated with improved functional status and quality of life,
|
|
independent of tumor response. Several studies of epoetin alfa and darbepoetin alfa employed a randomized, controlled design. These studies varied in terms of medication dosage and frequency of administration. A review and meta-analysis of randomized and open-label studies concluded that these agents are effective in the management of CRF [<a class="bk_pop" href="#CDR0000062734_rl_83_11">11</a>] but also raised serious concerns about safety data and adverse outcomes associated with these agents. The authors concluded that the risks associated with these agents outweigh their benefits for the treatment of CRF and therefore are not to be used.</p><p id="CDR0000062734__383">The FDA has conducted a comprehensive review of safety information from studies of these agents.[<a class="bk_pop" href="#CDR0000062734_rl_83_12">12</a>] The review showed that in patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers, erythropoiesis-stimulating agents (ESAs) shortened overall survival and/or increased the risk of tumor progression or recurrence. The review also showed that ESAs increase the risk of serious cardiovascular and thromboembolic events when they are administered to target higher hemoglobin levels (13.5–14 g/dL).</p><p id="CDR0000062734__384">On the basis of these findings, the FDA mandated revised ESA labeling to include an updated warning, a new boxed warning, and modifications to the indications and dosing instructions. The boxed warning includes information on the higher mortality risks caused by cardiovascular/thromboembolic events and tumor progression or recurrence. The 2010 American Society of Clinical Oncology (ASCO)/American Society of Hematology (ASH) guidelines recommend the following:[<a class="bk_pop" href="#CDR0000062734_rl_83_13">13</a>]</p><ul id="CDR0000062734__386"><li class="half_rhythm"><div>In accordance with the FDA-approved label,[<a class="bk_pop" href="#CDR0000062734_rl_83_14">14</a>] the use of these agents should be restricted to the treatment of anemia (hemoglobin level <10 g/dL) caused by concomitant palliative myelosuppressive chemotherapy and should be discontinued upon completion of a course of chemotherapy. (The above does not hold for low-risk myelodysplastic syndrome.)[<a class="bk_pop" href="#CDR0000062734_rl_83_13">13</a>]</div></li><li class="half_rhythm"><div>In accordance with the FDA-approved label, the lowest possible dose should be used, with the goal of avoiding red blood cell transfusions, because the higher doses increase the risk of cardiovascular and thromboembolic events.</div></li><li class="half_rhythm"><div>Initial dose and modification should follow FDA-approved labeling.[<a class="bk_pop" href="#CDR0000062734_rl_83_15">15</a>,<a class="bk_pop" href="#CDR0000062734_rl_83_16">16</a>] ESAs should be discontinued if there is no response after 6 to 8 weeks (<1–2 g/dL increase in hemoglobin or no decrease in transfusion requirements).</div></li><li class="half_rhythm"><div>The FDA-approved label states that ESAs are not indicated for patients receiving curative myelosuppressive chemotherapy. However, the 2010 ASCO/ASH recommendations state that clinical judgment, goals of therapy, and patient preference should guide ESA use in the curative and palliative settings.[<a class="bk_pop" href="#CDR0000062734_rl_83_13">13</a>]</div></li></ul><p id="CDR0000062734__387">A Cochrane review concluded that ESAs provide a clinically significant reduction in fatigue for anemic patients receiving chemotherapy.[<a class="bk_pop" href="#CDR0000062734_rl_83_11">11</a>] However, on the basis of safety concerns raised by the FDA and in view of identified side effects, this review further concluded that ESAs should not be used in clinical practice for fatigue.[<a class="bk_pop" href="#CDR0000062734_rl_83_11">11</a>]
|
|
Clinicians initiate discussions with patients and family members about the risks and benefits of ESAs.</p><p id="CDR0000062734__388">In February 2010, the FDA approved and mandated a risk management program to inform health care providers and their patients about the risk of ESAs.[<a class="bk_pop" href="#CDR0000062734_rl_83_12">12</a>,<a class="bk_pop" href="#CDR0000062734_rl_83_17">17</a>] This program includes a specific medication guide for patients that, along with the FDA public health advisory,[<a class="bk_pop" href="#CDR0000062734_rl_83_18">18</a>] states that ESAs are not approved or indicated for the treatment of fatigue in patients with cancer.</p></div><div id="CDR0000062734__86"><h3>Psychostimulants</h3><p id="CDR0000062734__261">One of the most popular categories of pharmacologic interventions evaluated for cancer-related fatigue (CRF) is psychostimulants (see <a class="figpopup" href="/books/NBK66049.2/table/CDR0000062734__289/?report=objectonly" target="object" rid-figpopup="figCDR0000062734289" rid-ob="figobCDR0000062734289">Table 2</a>). Psychostimulants are drugs that interact with neurotransmitters and receptors in the brain to increase cortical function. Different types of psychostimulants work through various mechanisms to produce activity in the brain consistent with short-term improvement in energy level and psychomotor activity. These medications may also improve mood, attention, and concentration in some populations. Psychostimulants on the market include the following:</p><ul id="CDR0000062734__313"><li class="half_rhythm"><div>Methylphenidate.</div></li><li class="half_rhythm"><div>Dextroamphetamine.</div></li><li class="half_rhythm"><div>Pemoline.</div></li><li class="half_rhythm"><div>Modafinil.</div></li><li class="half_rhythm"><div>Armodafinil.</div></li><li class="half_rhythm"><div>Nonprescription caffeine.</div></li></ul><p id="CDR0000062734__262">Initial support for the hypothesis that psychostimulants may improve CRF arises largely from clinical anecdotal experiences. These medications are not approved by the U.S. Food and Drug Administration (FDA) for the treatment of CRF. However, preliminary evidence from randomized controlled studies [<a class="bk_pop" href="#CDR0000062734_rl_83_19">19</a>-<a class="bk_pop" href="#CDR0000062734_rl_83_21">21</a>]
|
|
suggests that these medications might be helpful in a subpopulation of patients experiencing more severe fatigue. There are at least seven published randomized clinical trials evaluating psychostimulants for CRF: six with methylphenidate and one with modafinil. Only one of these randomized trials [<a class="bk_pop" href="#CDR0000062734_rl_83_19">19</a>] has shown significant differences between the placebo group and methylphenidate group with respect to the outcome of fatigue.</p><p id="CDR0000062734__310">The one study that demonstrated significant improvements over placebo for CRF used a mean dose of 27.7 mg of the D-isomer of methylphenidate as a study intervention.[<a class="bk_pop" href="#CDR0000062734_rl_83_19">19</a>] The population that benefited was women who had completed chemotherapy for breast or ovarian cancer. The study design incorporated a titration to effect, so some patients who may have benefited may have received more than 27.7 mg of the drug. Furthermore, 11% of participants on this trial withdrew because of adverse events, compared with 1% in the placebo arm. Conversely, an equally large randomized controlled trial randomly assigned patients with early and advanced disease, both on and off treatment, to receive 54 mg of a long-acting methylphenidate preparation equaling 27 mg of the D-isomer or a placebo; this trial found no differences between the two groups in any of the fatigue outcomes.[<a class="bk_pop" href="#CDR0000062734_rl_83_22">22</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663069/" class="def">Level of evidence: I</a>] There were significant differences between groups for nervousness and appetite loss, with the methylphenidate arm scoring worse on both of those side effects.</p><p id="CDR0000062734__264">The newer so-called wake-promoting agents, modafinil and armodafinil, are just beginning to be studied for CRF. Modafinil is a centrally acting, nonamphetamine, central nervous system stimulant.[<a class="bk_pop" href="#CDR0000062734_rl_83_23">23</a>] Armodafinil is the R-enantiomer of modafinil and an alpha-1 adrenoceptor agonist.[<a class="bk_pop" href="#CDR0000062734_rl_83_24">24</a>] Modafinil and armodafinil are approved by the FDA for narcolepsy, obstructive sleep apnea, and shift-work disorders. Neither of these agents is approved by the FDA for the treatment of CRF. These agents are also not indicated for use in children and adolescents. The mechanism of action of modafinil and armodafinil is different from that of amphetamines, but the exact mechanisms by which these agents improve wakefulness are not known. On the basis of a couple of promising open-label pilot trials,[<a class="bk_pop" href="#CDR0000062734_rl_83_25">25</a>,<a class="bk_pop" href="#CDR0000062734_rl_83_26">26</a>] a large randomized controlled trial evaluated modafinil for CRF using 200 mg versus placebo in more than 850 patients receiving chemotherapy. Patients had to have fatigue ratings of at least 2 out of 10 to be eligible for this study. During four cycles of chemotherapy, this study failed to show significant differences between arms.[<a class="bk_pop" href="#CDR0000062734_rl_83_21">21</a>] Because armodafinil is newer to the marketplace, research on its possible role in CRF has not yet been published. More research is needed to identify whether modafinil and armodafinil can ameliorate fatigue and which populations of cancer survivors can benefit most from them.</p><p id="CDR0000062734__265">With both methylphenidate and modafinil, there have been exploratory data suggesting that patients with more severe fatigue or more advanced disease may receive more benefit from these drugs.[<a class="bk_pop" href="#CDR0000062734_rl_83_21">21</a>,<a class="bk_pop" href="#CDR0000062734_rl_83_22">22</a>] A small (n = 13), randomized, placebo-controlled study [<a class="bk_pop" href="#CDR0000062734_rl_83_20">20</a>] using methylphenidate (titrated up to 30 mg/day) as an intervention failed to show statistical difference on the primary outcome measure, the Brief Fatigue Inventory (BFI) total score, or activity interference subscale. However, the methylphenidate group showed significant reductions in the BFI severity subscale scores compared with the reductions seen in the placebo group. The mean severity score at baseline was 6.5 for the methylphenidate group and 5.7 for the placebo group, placing these patients in a more severe fatigue category. A secondary analysis of the phase III trial that evaluated modafinil versus placebo for CRF also revealed that patients with more severe fatigue may have benefited from modafinil.[<a class="bk_pop" href="#CDR0000062734_rl_83_21">21</a>] More research is needed to further evaluate whether psychostimulants are beneficial for patients experiencing more severe CRF.</p><p id="CDR0000062734__267">The side effects most commonly described with psychostimulants include the following:[<a class="bk_pop" href="#CDR0000062734_rl_83_19">19</a>,<a class="bk_pop" href="#CDR0000062734_rl_83_21">21</a>,<a class="bk_pop" href="#CDR0000062734_rl_83_22">22</a>,<a class="bk_pop" href="#CDR0000062734_rl_83_27">27</a>,<a class="bk_pop" href="#CDR0000062734_rl_83_28">28</a>]</p><ul id="CDR0000062734__348"><li class="half_rhythm"><div> Insomnia.</div></li><li class="half_rhythm"><div>Euphoria.</div></li><li class="half_rhythm"><div>Headache.</div></li><li class="half_rhythm"><div>Nausea.</div></li><li class="half_rhythm"><div>Anxiety.</div></li><li class="half_rhythm"><div> Mood lability.</div></li></ul><p id="CDR0000062734__349"> High doses and long-term use may produce:</p><ul id="CDR0000062734__350"><li class="half_rhythm"><div> Anorexia.</div></li><li class="half_rhythm"><div>Nightmares.</div></li><li class="half_rhythm"><div>Insomnia.</div></li><li class="half_rhythm"><div>Euphoria.</div></li><li class="half_rhythm"><div>Paranoia.</div></li><li class="half_rhythm"><div>Possible cardiovascular complications.</div></li></ul><p id="CDR0000062734__351">Patients with cancer carry a higher risk of cardiovascular complications, depending on the type of cancer and cancer treatment (e.g., cardiotoxic chemotherapy regimens). Cardiovascular complications with psychostimulants can arise even in patients without any significant risk factors.[<a class="bk_pop" href="#CDR0000062734_rl_83_20">20</a>] In the study using methylphenidate as an intervention for the treatment of CRF in patients with prostate cancer, 6 of 16 subjects (27%) in the methylphenidate group were discontinued because of increased blood pressure and tachycardia. It is important to note that none of these subjects were being treated with known cardiotoxic chemotherapeutic regimens such as anthracyclines.[<a class="bk_pop" href="#CDR0000062734_rl_83_20">20</a>] Careful and continuous monitoring of certain cardiovascular parameters (mainly blood pressure and heart rate) is critical when psychostimulants are used to treat CRF. In certain complex cases, consulting with cardiology services may be considered. Cardiovascular issues are thought to be less of a risk with modafinil and armodafinil. Risk-benefit ratio may be considered and patients may be evaluated for response and side effects when these agents are used to treat CRF.</p><p id="CDR0000062734__268">The package inserts for all Schedule IV stimulant medications carry boxed warnings indicating risk of abuse potential and/or risk of psychological dependence. Additionally, boxed warnings for certain stimulant medications (methylphenidate and dexmethylphenidate products) indicate risk of psychotic episodes.[<a class="bk_pop" href="#CDR0000062734_rl_83_27">27</a>] Other stimulant medications (amphetamine, dextroamphetamine, lisdexamfetamine dimesylate, methamphetamine, and mixed salts of amphetamine products) carry boxed warnings alerting clinicians that misuse of these medications may cause serious cardiovascular adverse events, including sudden
|
|
death.[<a class="bk_pop" href="#CDR0000062734_rl_83_29">29</a>]</p><div id="CDR0000062734__289" class="table"><h3><span class="title">Table 2. Centrally Acting Stimulants for Adult Cancer Patients</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK66049.2/table/CDR0000062734__289/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__CDR0000062734__289_lrgtbl__"><table class="no_margin"><thead><tr><th colspan="1" rowspan="1" style="vertical-align:top;">Drug</th><th colspan="1" rowspan="1" style="vertical-align:top;">Dosage</th><th colspan="1" rowspan="1" style="vertical-align:top;">Comments/Primary Side Effects</th></tr></thead><tbody><tr><td colspan="1" rowspan="2" style="vertical-align:top;">Dextroamphetamine (Dexedrine)</td><td colspan="1" rowspan="1" style="vertical-align:top;">2.5 mg/d (start)</td><td colspan="1" rowspan="2" style="vertical-align:top;">Schedule II. Major potential interactions with citalopram and venlafaxine.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">5–30 mg/d in 2 to 3 divided doses</td></tr><tr><td colspan="1" rowspan="2" style="vertical-align:top;">Methylphenidate (Ritalin)</td><td colspan="1" rowspan="1" style="vertical-align:top;">2.5 mg/d (start)</td><td colspan="1" rowspan="2" style="vertical-align:top;">Schedule II. High-fat meals may increase AUC. Peak concentration 102 hours after ingestion. Do not use with MAOIs as it can precipitate hypertensive crisis. Antidepressants that increase norepinephrine can cause increased amphetamine side effects. Concomitant use with SSRI can result in increased SSRI concentrations.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">Titrate up to 54 mg/d (27 mg D-isomer)</td></tr><tr><td colspan="1" rowspan="2" style="vertical-align:top;">Modafinil (Provigil)</td><td colspan="1" rowspan="1" style="vertical-align:top;">50–100 mg (start)</td><td colspan="1" rowspan="2" style="vertical-align:top;">Schedule IV. Avoid driving/operation of machinery until effects are known. Do not take at bedtime. Peak concentration in 2–4 hours. Food slows absorption by about 1 hour but does not affect bioavailability. Decreases efficacy of birth control pills.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">100–200 mg every morning</td></tr><tr><td colspan="1" rowspan="2" style="vertical-align:top;">Armodafinil (Nuvigil)</td><td colspan="1" rowspan="1" style="vertical-align:top;">50 mg (start)</td><td colspan="1" rowspan="2" style="vertical-align:top;">Schedule IV. Avoid driving/operation of machinery until effects are known. Do not take at bedtime. Peak concentration in 2 hours if fasting, slowed to as many as 4 hours if fed, but food does not affect bioavailability. Decreases efficacy of birth control pills.</td></tr><tr><td colspan="1" rowspan="1" style="vertical-align:top;">25–250 mg every morning</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AUC = area under the curve; MAOI = monoamine oxidase inhibitor; SSRI = selective serotonin reuptake inhibitor.</p></div></dd></dl></div></div></div><p id="CDR0000062734__90">On the basis of limited clinical experience and acknowledging a lack of evidence in randomized controlled trials, it might be reasonable to consider a psychostimulant such as methylphenidate or modafinil for the treatment of severe fatigue, particularly for short periods of time (a couple of weeks) in patients with advanced disease. When the use of these medications is being considered, it is important to obtain informed consent, with careful discussion of risks, benefits, and alternatives. Continuous monitoring of cardiovascular parameters is crucial when these medications are used, especially in patients with preexisting cardiovascular issues and in patients being treated with known cardiotoxic chemotherapeutic regimens (e.g., anthracyclines). In certain cases, consulting with cardiology services might be necessary. Longer-term psychostimulant therapy is not advisable at this time because there is limited information about its potential negative effects and longer-term benefits.</p></div><div id="CDR0000062734__356"><h3>Other Pharmacologic Interventions</h3><div id="CDR0000062734__366"><h4>Bupropion</h4><p id="CDR0000062734__367">Bupropion is a stimulating antidepressant with a primarily dopaminergic and noradrenergic mechanism of action. Preliminary evidence from a small open-label study (N = 21) suggests that the sustained-release (SR) form of bupropion has potential as an effective therapeutic agent for treating CRF with or without comorbid depressive symptoms.[<a class="bk_pop" href="#CDR0000062734_rl_83_30">30</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663072/" class="def">Level of evidence: II</a>] Seizure, a rare but serious side effect of this agent, did not occur in this study (the maximum dose of bupropion SR used in this study was 300 mg).</p></div><div id="CDR0000062734__368"><h4>Dexamethasone</h4><p id="CDR0000062734__369">Dexamethasone is a potent anti-inflammatory agent that has recently been evaluated for the treatment of fatigue in patients with advanced cancer. Eighty-four patients were randomly assigned to receive either dexamethasone 4 mg twice per day or a placebo for 14 days. The primary endpoint was improvement in fatigue from baseline to day 15, as measured by the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) scale. Investigators also evaluated depression, anxiety, and symptom distress. In the group who received dexamethasone, mean scores on the FACIT-F scale were significantly improved by day 8 (<i>P</i> = .005) and at day 15 (<i>P</i> = .008). Physical well-being and physical distress were also significantly better in the group who received dexamethasone. Emotional scores and overall symptom distress were not significantly different. Adverse events, as measured by the Common Terminology Criteria for Adverse Events, version 3.0, did not differ between groups.</p><p id="CDR0000062734__370">One limitation of this study was that it was only 2 weeks long, and longer-term use of dexamethasone is well known to be associated with unwanted side effects. Therefore, the risk versus benefit of treating fatigue with dexamethasone for more than 2 weeks requires investigation. Because fatigue has been associated with high levels of inflammation, this study is noteworthy in its evaluation of dexamethasone as an anti-inflammatory agent to alleviate fatigue.[<a class="bk_pop" href="#CDR0000062734_rl_83_31">31</a>] The investigators did not assess inflammatory biomarkers; therefore, the proof of concept that modifying inflammation can reduce fatigue needs replication.</p></div><div id="CDR0000062734__371"><h4>Dietary supplements</h4><p id="CDR0000062734__372">Dietary supplements comprise other, often popular, pharmacologic interventions for CRF.</p><div id="CDR0000062734__373"><h5>L-carnitine</h5><p id="CDR0000062734__374">L-carnitine is a widely used dietary supplement believed to be helpful for the treatment of CRF because of its role in cellular energy metabolism and carnitine’s ability to decrease pro-inflammatory cytokines. Promising pilot data led to the development and completion of a large (N = 376) phase III study in a multisite cooperative group setting. Participants with moderate to severe fatigue were randomly assigned to receive either 10 g levocarnitine or a placebo for 4 weeks. The primary endpoint was change in average fatigue. Despite increases in mean levels of L-carnitine, there was not a statistically significant difference in fatigue between arms, with both arms reporting improved fatigue during the study.[<a class="bk_pop" href="#CDR0000062734_rl_83_32">32</a>]</p></div><div id="CDR0000062734__375"><h5>Ginseng</h5><p id="CDR0000062734__376">Ginseng, another popular supplement used to treat fatigue, has also been the subject of evaluation in large, multisite clinical trials. On the basis of a promising phase II dose-finding study,[<a class="bk_pop" href="#CDR0000062734_rl_83_33">33</a>] a phase III, randomized, placebo-controlled trial was completed involving 364 patients with cancer who either were undergoing anticancer treatment or had completed treatment. Participants were randomly assigned to receive either 2,000 mg of American ginseng (specifically, Wisconsin ginseng) in the form of ground root in a capsule or a matching placebo. The primary endpoint was change in fatigue scores as measured by the Multidimensional Fatigue Symptom Inventory-Short Form. At 4 weeks, the group receiving ginseng showed a trend toward significant improvement, while at 8 weeks, there was a significant and clinically meaningful difference favoring the ginseng group. There were no discernible side effects during the course of the trial, either within or between groups.[<a class="bk_pop" href="#CDR0000062734_rl_83_34">34</a>]</p></div></div></div><div id="CDR0000062734__94"><h3>Exercise</h3><p id="CDR0000062734__95"> Preliminary studies [<a class="bk_pop" href="#CDR0000062734_rl_83_35">35</a>-<a class="bk_pop" href="#CDR0000062734_rl_83_37">37</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663069/" class="def">Level of evidence: I</a>];[<a class="bk_pop" href="#CDR0000062734_rl_83_38">38</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663072/" class="def">Level of evidence: II</a>];[<a class="bk_pop" href="#CDR0000062734_rl_83_39">39</a>,<a class="bk_pop" href="#CDR0000062734_rl_83_40">40</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663087/" class="def">Level of evidence: III</a>];[<a class="bk_pop" href="#CDR0000062734_rl_83_41">41</a>
|
|
,<a class="bk_pop" href="#CDR0000062734_rl_83_42">42</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663089/" class="def">Level of evidence: IV</a>] suggest that exercise (including light- to
|
|
moderate-intensity walking programs) has potential benefits for people with
|
|
cancer. The benefits shown in these studies and observed in clinical settings
|
|
include improved physical energy, appetite stimulation, and/or enhanced
|
|
functional capacity, with improvements in quality of life and in
|
|
many aspects of psychologic state (e.g., improved outlook and sense of well-being, enhanced sense of commitment, and the ability to meet the challenges of
|
|
cancer and cancer treatment).</p><p id="CDR0000062734__304">Several reviews and National Comprehensive Cancer Network guidelines outline numerous studies that support the beneficial effects of exercise on fatigue.[<a class="bk_pop" href="#CDR0000062734_rl_83_43">43</a>,<a class="bk_pop" href="#CDR0000062734_rl_83_44">44</a>] Reductions in fatigue of about 35% and improvements in vitality of 30% have been shown in randomized trials, with stronger effects being shown during cancer therapy in some studies and after therapy in other studies.[<a class="bk_pop" href="#CDR0000062734_rl_83_43">43</a>,<a class="bk_pop" href="#CDR0000062734_rl_83_45">45</a>] Many initial trials of exercise programs focused on women with breast cancer, but later studies included men with prostate cancer, multiple myeloma, and colorectal cancer.[<a class="bk_pop" href="#CDR0000062734_rl_83_46">46</a>] Some studies have had methodologic weaknesses, including the following:[<a class="bk_pop" href="#CDR0000062734_rl_83_47">47</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663069/" class="def">Level of evidence: I</a>]</p><ul id="CDR0000062734__232"><li class="half_rhythm"><div>Selection biases and nonrepresentative
|
|
samples.</div></li><li class="half_rhythm"><div>Recruitment of patients into randomized trials.</div></li><li class="half_rhythm"><div>Poor adherence to exercise interventions.</div></li><li class="half_rhythm"><div>Highly varied assessments of research variables and outcome measures.</div></li><li class="half_rhythm"><div>Lack of adequate control groups.</div></li></ul><p id="CDR0000062734__233">
|
|
Some examples of the breadth of trials evaluating exercise are discussed in the following paragraphs. One study of patients undergoing peripheral blood stem cell transplantation found
|
|
symptomatic benefits and improvements in mood in patients who participated in
|
|
the interval-training program versus the control group.[<a class="bk_pop" href="#CDR0000062734_rl_83_48">48</a>,<a class="bk_pop" href="#CDR0000062734_rl_83_49">49</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663069/" class="def">Level of evidence: I</a>] Supervised aerobic group exercise provided functional and quality-of-life benefits for women during treatment for breast cancer.[<a class="bk_pop" href="#CDR0000062734_rl_83_50">50</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663069/" class="def">Level of evidence: I</a>] Exercise improved function in patients treated for breast cancer.[<a class="bk_pop" href="#CDR0000062734_rl_83_51">51</a>,<a class="bk_pop" href="#CDR0000062734_rl_83_52">52</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663069/" class="def">Level of evidence: I</a>]</p><p id="CDR0000062734__234"> In a study of 545 breast cancer survivors who were, on average, 6 months postdiagnosis, increased physical activity was consistently related to both improved physical functioning and reduced fatigue and bodily pain. Prediagnosis physical activity was associated with better physical functioning at 39 months but generally unrelated to symptoms. Increased physical activity after cancer was related to less fatigue and pain and better physical functioning. Significant positive associations were found with moderate to vigorous recreational physical activity but not household activity. This study suggests that breast cancer survivors may be able to decrease fatigue and bodily pain and be better able to pursue daily activities by increasing their recreational physical activities after cancer.[<a class="bk_pop" href="#CDR0000062734_rl_83_53">53</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663072/" class="def">Level of evidence: II</a>]</p><p id="CDR0000062734__96">Exercise for patients with advanced or terminal disease is difficult to study
|
|
but may yield similar benefits. The ability of patients with advanced cancer
|
|
who are in hospice care and on a physical therapy regimen to carry out
|
|
activities of daily living has been reported to improve in one study.[<a class="bk_pop" href="#CDR0000062734_rl_83_54">54</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663087/" class="def">Level of evidence: III</a>]
|
|
Improved satisfaction with the physical therapy regimen was reported when
|
|
family involvement in the program increased. A randomized study suggested that exercise improved fatigue during breast cancer treatment.[<a class="bk_pop" href="#CDR0000062734_rl_83_55">55</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663069/" class="def">Level of evidence: I</a>]</p><p id="CDR0000062734__272">When educating patients about activity with respect to CRF, one important goal to consider is inclusion of 3 to 5 hours per week of moderate activity. It is critical that:</p><ul id="CDR0000062734__306"><li class="half_rhythm"><div>Patients choose a type of exercise they enjoy.</div></li><li class="half_rhythm"><div>Providers discuss specific implementation strategies (type of exercise, time of day, days of the week, location of activity) to enable patients to make frequent activity a reality.</div></li></ul><p id="CDR0000062734__307">Beginning with lighter activity for shorter periods of time and building in intensity and length of time may be required. Studies have confirmed this can be safely done both during active treatment and after treatment is completed.[<a class="bk_pop" href="#CDR0000062734_rl_83_45">45</a>]</p><p id="CDR0000062734__269">Variations of exercise that have a mind-body component include complementary modalities such as qigong, tai chi, and yoga, popular interventions that are being studied for their effects on CRF. These modalities are unique in that they incorporate cognitive and spiritual elements with movement, stretching, and balance. One fairly large study evaluated medical qigong for CRF in a heterogeneous group of 162 patients either undergoing cancer treatment or having finished cancer treatment.[<a class="bk_pop" href="#CDR0000062734_rl_83_56">56</a>] This study reported significant improvements in fatigue and several other aspects of quality of life for the intervention group versus usual care.</p><p id="CDR0000062734__305">The qigong intervention was delivered in 90-minute group sessions twice a week for 10 weeks, for 1,800 minutes of treatment. The usual-care group did not receive any group meetings or additional provider interaction. It is therefore difficult to say what qigong uniquely provided over and above nonspecific or group-interaction effects. It is also not known how much survivors would need to continue performing qigong to maintain benefits. There were no adverse events in this study, so other than time and resource expenditure, it is difficult to pinpoint a downside to encouraging patients to adopt such an activity. One important strength of the study evaluating qigong was the collection of serum to measure markers of inflammation. At the end of 10 weeks, the C-reactive protein of patients in the medical qigong group decreased 3.6 mg/L, while patients in the usual-care group experienced an increase in this marker of 19.57 mg/L. This was a statistically significant difference.[<a class="bk_pop" href="#CDR0000062734_rl_83_56">56</a>]</p><p id="CDR0000062734__362">A second, smaller study (N = 96) that compared a qigong group to a wait-list control group evaluated fatigue using the BFI as a secondary outcome and also assessed a biologic measure, salivary cortisol. This study did not find any significant difference in fatigue or cortisol between groups. The intervention dose in this study, comprising five 40-minute sessions over 6 weeks of radiation therapy in women diagnosed with breast cancer, was much lower than the intervention dose in the larger study described above.[<a class="bk_pop" href="#CDR0000062734_rl_83_57">57</a>]</p><p id="CDR0000062734__363"> The major weakness limiting interpretation and integration of both of these studies, despite differing results, is that there was no attempt to control for attention or any of the social aspects of the intervention.</p></div><div id="CDR0000062734__172"><h3>Cognitive Behavior Therapy</h3><p id="CDR0000062734__173">Cognitive behavior therapy (CBT) has long been used to treat a variety of psychophysiological problems, with therapy focusing on the thoughts (cognitions) and functional behaviors relevant to the presenting problems. In a randomized clinical trial, 98 mixed-type cancer survivors (intervention group = 50, wait-list control = 48) experiencing severe fatigue not attributable to a specific somatic cause were provided individual CBT.[<a class="bk_pop" href="#CDR0000062734_rl_83_58">58</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663069/" class="def">Level of evidence: I</a>] The CBT focused on each participant's unique pattern of the following six possible factors that might serve to perpetuate their post–cancer treatment fatigue:</p><ul id="CDR0000062734__311"><li class="half_rhythm"><div>Insufficient coping with the experience of cancer.</div></li><li class="half_rhythm"><div>Fear of disease recurrence.</div></li><li class="half_rhythm"><div>Dysfunctional cognitions regarding fatigue.</div></li><li class="half_rhythm"><div>Dysregulation of sleep.</div></li><li class="half_rhythm"><div>Dysregulation of activity.</div></li><li class="half_rhythm"><div>Low social support/negative social interactions.</div></li></ul><p id="CDR0000062734__312">The number of therapy sessions varied according to the number of perpetuating factors (range: 5–26 1-hour sessions; mean: 12.5 sessions); results showed a clinically significant decrease in fatigue severity and functional impairment.</p></div><div id="CDR0000062734__97"><h3>Activity and Rest</h3><p id="CDR0000062734__98">Health professionals can work with patients with cancer to develop an
|
|
activity/rest program based on an assessment of the patient’s fatigue patterns
|
|
that allows the best use of the individual’s energy. Any changes in daily
|
|
routine require additional energy expenditure. Individuals with cancer are advised about setting priorities and maintaining a reasonable schedule.
|
|
Health professionals may assist patients by providing information on support
|
|
services that are available to help with daily activities and responsibilities.
|
|
An occupational therapy consultation can be of assistance in evaluating energy
|
|
conservation methods. Sleep hygiene, including avoidance of lying in bed at
|
|
times other than sleep, shortening naps to no more than 1 hour, avoiding
|
|
distracting noise (e.g., television, radio) during sleep hours, and other measures may
|
|
improve sleep and activity cycles.
|
|
</p></div><div id="CDR0000062734__99"><h3>Patient Education</h3><p id="CDR0000062734__100">Much of the management of chronic fatigue in people with cancer involves
|
|
promoting adaptation and adjustment to the condition. The possibility that
|
|
fatigue may be a chronic disability may be discussed. Although fatigue is
|
|
frequently an expected, temporary side effect of treatment, the problem may
|
|
persist if other factors continue to be present.
|
|
</p><p id="CDR0000062734__101">An important goal of management is to facilitate self-care for the person with
|
|
cancer. Since fatigue is documented as the most commonly reported symptom in
|
|
individuals receiving outpatient chemotherapy (81% of cancer patients report
|
|
fatigue),[<a class="bk_pop" href="#CDR0000062734_rl_83_59">59</a>] a shift in responsibility for control of side effects from the
|
|
health care professional to the individual is important.[<a class="bk_pop" href="#CDR0000062734_rl_83_60">60</a>] It is imperative that
|
|
individuals with cancer are educated about fatigue before it occurs and are taught about self-care strategies
|
|
necessary to manage fatigue.</p><p id="CDR0000062734__102">Specific techniques for the management of fatigue include the following:
|
|
</p><ul id="CDR0000062734__103"><li class="half_rhythm"><div>Differentiation of fatigue from depression.</div></li><li class="half_rhythm"><div>Assessment for presence of correctable correlates or causes of fatigue
|
|
(e.g., dehydration, electrolyte imbalance, dyspnea, anemia).</div></li><li class="half_rhythm"><div>Evaluation of patterns of rest and activity during the day as well as over
|
|
time.</div></li><li class="half_rhythm"><div>Determination of the level of attentional fatigue and encouragement of the
|
|
planned use of attention-restoring activities (e.g., walking, gardening,
|
|
bird watching).</div></li><li class="half_rhythm"><div>Providing anticipatory guidance regarding the likelihood of experiencing
|
|
fatigue, and the fatigue patterns associated with particular treatments.</div></li><li class="half_rhythm"><div>Encouragement of activity/planned exercise programs within individual
|
|
limitations; making goals realistic by keeping in mind the state of disease
|
|
and treatment regimens.</div></li><li class="half_rhythm"><div>Education of individuals and families about fatigue related to cancer and
|
|
its treatment.</div></li><li class="half_rhythm"><div>Helping people with cancer and their families identify fatigue-promoting
|
|
activities and develop specific strategies to modify these activities.</div></li><li class="half_rhythm"><div>Suggesting individualized environmental or activity changes that may offset
|
|
fatigue.</div></li><li class="half_rhythm"><div>Maintaining adequate hydration and nutrition.</div></li><li class="half_rhythm"><div>Recommending physical therapy referral for people with specific
|
|
neuromusculoskeletal deficits.</div></li><li class="half_rhythm"><div>Recommending respiratory therapy referral for people with dyspnea that is
|
|
a contributing factor to fatigue.</div></li><li class="half_rhythm"><div>Scheduling important daily activities during times of least fatigue and
|
|
eliminating nonessential, stress-producing activities.
|
|
</div></li><li class="half_rhythm"><div>Addressing the negative impact of psychologic and social stressors and
|
|
how to avoid or modify them.
|
|
</div></li><li class="half_rhythm"><div>Evaluating the efficacy of fatigue interventions on a regular and
|
|
systematic basis.[<a class="bk_pop" href="#CDR0000062734_rl_83_61">61</a>]
|
|
</div></li></ul><p id="CDR0000062734__122">In a controlled trial of patients who reported the symptom cluster of pain and fatigue while receiving chemotherapy, a nursing behavioral intervention produced improvements in quality of life and decreased symptom burden relative to usual care.[<a class="bk_pop" href="#CDR0000062734_rl_83_62">62</a>,<a class="bk_pop" href="#CDR0000062734_rl_83_63">63</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663069/" class="def">Level of evidence: I</a>] These intriguing results need to be further explored in patient populations other than women with breast or gynecologic malignancies.</p><p id="CDR0000062734__273">As researchers and practitioners learned with pain, misconceptions and a lack of knowledge may prove to be patient- and provider-related barriers to successful assessment and management. A quasi-experimental study tested a multisystem educational approach to improving both pain and fatigue management.[<a class="bk_pop" href="#CDR0000062734_rl_83_64">64</a>] The approach consisted of the following:</p><ul id="CDR0000062734__274"><li class="half_rhythm"><div>Education and assessment of patients regarding the management of pain and fatigue, with phone calls every 2 weeks for 3 months.</div></li><li class="half_rhythm"><div>Education of providers about pain and fatigue assessment and management, including monthly newsletters.</div></li><li class="half_rhythm"><div>An effort to engage with an internal advisory board.</div></li><li class="half_rhythm"><div>Efforts aimed toward research nurses to refer earlier to supportive care services.</div></li></ul><p id="CDR0000062734__275">Over a 3-month period, the educational intervention resulted in increases in knowledge and a decrease in barriers related to management of pain and fatigue. Of note, important patient barriers related to fatigue management included the following beliefs:[<a class="bk_pop" href="#CDR0000062734_rl_83_64">64</a>][<a href="/books/n/pdqcis/glossary_loe/def-item/glossary_loe_CDR0000663072/" class="def">Level of evidence: II</a>]</p><ul id="CDR0000062734__276"><li class="half_rhythm"><div>Fatigue is inevitable.</div></li><li class="half_rhythm"><div>Fatigue can indicate worsening of disease.</div></li><li class="half_rhythm"><div>Treating the cancer is more important than treating fatigue.</div></li><li class="half_rhythm"><div>Reporting fatigue will cause a patient to be perceived as a complainer.</div></li></ul></div><div id="CDR0000062734__TrialSearch_83_sid_5"><h3>Current Clinical Trials</h3><p id="CDR0000062734__TrialSearch_83_13">Check the list of NCI-supported cancer clinical trials for supportive and palliative care trials about
|
|
<a href="http://www.cancer.gov/search/ClinicalTrialsLink.aspx?Diagnosis=41390&tt=2&format=2" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">fatigue</a> and <a href="http://www.cancer.gov/search/ClinicalTrialsLink.aspx?Diagnosis=41382&tt=2&format=2" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">anemia</a> that are now accepting participants. The list of trials can be further narrowed by location, drug, intervention, and other criteria. </p><p id="CDR0000062734__TrialSearch_83_14">General information about clinical trials is also available from the <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NCI website</a>.</p></div><div id="CDR0000062734_rl_83"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062734_rl_83_1">Arendt J, Borbely AA, Franey C, et al.: The effects of chronic, small doses of melatonin given in the late afternoon on fatigue in man: a preliminary study. Neurosci Lett 45 (3): 317-21, 1984. [<a href="https://pubmed.ncbi.nlm.nih.gov/6728321" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6728321</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_2">Glaspy J, Bukowski R, Steinberg D, et al.: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 15 (3): 1218-34, 1997. [<a href="https://pubmed.ncbi.nlm.nih.gov/9060566" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9060566</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_3">Gibson H, Edwards RH: Muscular exercise and fatigue. Sports Med 2 (2): 120-32, 1985 Mar-Apr. [<a href="https://pubmed.ncbi.nlm.nih.gov/3847097" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3847097</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_4">Hart LK: Fatigue in the patient with multiple sclerosis. Res Nurs Health 1 (4): 147-57, 1978.</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_5">de Raaf PJ, de Klerk C, Timman R, et al.: Systematic monitoring and treatment of physical symptoms to alleviate fatigue in patients with advanced cancer: a randomized controlled trial. J Clin Oncol 31 (6): 716-23, 2013. [<a href="https://pubmed.ncbi.nlm.nih.gov/23284036" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23284036</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_6">Armitage JO: Management of anemia in patients with cancer. Clinical Oncology Updates 1: 1-12, 1998.</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_7">Kotasek D, Steger G, Faught W, et al.: Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 39 (14): 2026-34, 2003. [<a href="https://pubmed.ncbi.nlm.nih.gov/12957457" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12957457</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_8">Hedenus M, Adriansson M, San Miguel J, et al.: Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 122 (3): 394-403, 2003. [<a href="https://pubmed.ncbi.nlm.nih.gov/12877666" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12877666</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_9">Demetri GD, Kris M, Wade J, et al.: Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16 (10): 3412-25, 1998. [<a href="https://pubmed.ncbi.nlm.nih.gov/9779721" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9779721</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_10">Osterborg A, Brandberg Y, Molostova V, et al.: Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies. J Clin Oncol 20 (10): 2486-94, 2002. [<a href="https://pubmed.ncbi.nlm.nih.gov/12011126" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12011126</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_11">Minton O, Richardson A, Sharpe M, et al.: Drug therapy for the management of cancer-related fatigue. Cochrane Database Syst Rev 7: CD006704, 2010. [<a href="https://pubmed.ncbi.nlm.nih.gov/20614448" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20614448</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_12">U.S. Food and Drug Administration: FDA Drug Safety Communication: Erythropoiesis-stimulating Agents (ESAs): Procrit, Epogen and Aranesp. Silver Spring, Md: U.S. Food and Drug Administration, 2010. <a href="https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm200297.htm" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">Available online</a>. Last accessed January 13, 2017.</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_13">Rizzo JD, Brouwers M, Hurley P, et al.: American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 28 (33): 4996-5010, 2010. [<a href="https://pubmed.ncbi.nlm.nih.gov/20975064" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20975064</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_14">Medication Guide: Aranesp (darbepoetin alfa). Thousand Oaks, Calif: Amgen Inc., 2012. <a href="https://www.fda.gov/downloads/Drugs/DrugSafety/ucm085918.pdf" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">Available online</a>. Last accessed January 13, 2017.</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_15">Procrit Label and Epogen Label. Silver Spring, Md: U.S. Food and Drug Administration, 2010. <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103234s5199lbl.pdf" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">Available online</a>. Last accessed January 13, 2017.</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_16">Aranesp (darbepoetin alfa) Label. Silver Spring, Md: U.S. Food and Drug Administration, 2010. <a href="http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/103951s5197lbl.pdf" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">Available online</a>. Last accessed January 13, 2017.</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_17">U.S. Food and Drug Administration: FDA announces new safety plan for agents used to treat chemotherapy-related anemia. Silver Spring, Md: U.S. Food and Drug Administration, 2010. <a href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm200471.htm" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">Available online</a>. Last accessed January 13, 2017.</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_18">U.S. Food and Drug Administration: Information on Erythropoiesis-stimulating Agents (ESAs): Epoetin alfa (marketed as Procrit, Epogen), Darbepoetin alfa (marketed as Aranesp). Silver Spring, Md: Food and Drug Administration, 2010. <a href="https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm109375.htm" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">Available online</a>. Last accessed January 13, 2017.</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_19">Lower EE, Fleishman S, Cooper A, et al.: Efficacy of dexmethylphenidate for the treatment of fatigue after cancer chemotherapy: a randomized clinical trial. J Pain Symptom Manage 38 (5): 650-62, 2009. [<a href="https://pubmed.ncbi.nlm.nih.gov/19896571" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19896571</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_20">Roth AJ, Nelson C, Rosenfeld B, et al.: Methylphenidate for fatigue in ambulatory men with prostate cancer. Cancer 116 (21): 5102-10, 2010. [<a href="/pmc/articles/PMC3632439/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3632439</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20665492" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20665492</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_21">Jean-Pierre P, Morrow GR, Roscoe JA, et al.: A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy: a University of Rochester Cancer Center Community Clinical Oncology Program Research base study. Cancer 116 (14): 3513-20, 2010. [<a href="/pmc/articles/PMC2941794/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2941794</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20564068" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20564068</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_22">Moraska AR, Sood A, Dakhil SR, et al.: Phase III, randomized, double-blind, placebo-controlled study of long-acting methylphenidate for cancer-related fatigue: North Central Cancer Treatment Group NCCTG-N05C7 trial. J Clin Oncol 28 (23): 3673-9, 2010. [<a href="/pmc/articles/PMC2917307/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2917307</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20625123" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20625123</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_23">Medication Guide: PROVIGIL (modafinil) Tablets. North Wales, Pa: Teva Pharmaceuticals USA, Inc., 2015. <a href="https://www.fda.gov/downloads/Drugs/DrugSafety/UCM231722.pdf" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">Available online</a>. Last accessed January 13, 2017.</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_24">Medication Guide: NUVIGIL (armodafinil) Tablets. North Wales, Pa: Teva Pharmaceuticals USA, Inc., 2015. <a href="https://www.fda.gov/downloads/Drugs/DrugSafety/UCM231717.pdf" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">Available online</a>. Last accessed January 13, 2017.</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_25">Blackhall L, Petroni G, Shu J, et al.: A pilot study evaluating the safety and efficacy of modafinal for cancer-related fatigue. J Palliat Med 12 (5): 433-9, 2009. [<a href="https://pubmed.ncbi.nlm.nih.gov/19416039" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19416039</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_26">Spathis A, Dhillan R, Booden D, et al.: Modafinil for the treatment of fatigue in lung cancer: a pilot study. Palliat Med 23 (4): 325-31, 2009. [<a href="https://pubmed.ncbi.nlm.nih.gov/19270033" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19270033</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_27">CONCERTA (methylphenidate HCl) Extended-release Tablets. Titusville, NJ: Janssen Pharmaceuticals, Inc., 2013. <a href="http://www.concerta.net/pdfs/Prescribing_Info-short.pdf" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">Available online</a>. Last accessed January 13, 2017.</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_28">Prommer E: Modafinil: is it ready for prime time? J Opioid Manag 2 (3): 130-6, 2006 May-Jun. [<a href="https://pubmed.ncbi.nlm.nih.gov/17319446" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17319446</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_29">ADDERALL XR (mixed salts of a single-entity amphetamine), CII. Lexington, Mass: Shire US Inc., 2015. <a href="http://www.shirecontent.com/PI/PDFS/AdderallXR_USA_ENG.PDF" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">Available online</a>. Last accessed January 13, 2017.</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_30">Moss EL, Simpson JS, Pelletier G, et al.: An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners. Psychooncology 15 (3): 259-67, 2006. [<a href="https://pubmed.ncbi.nlm.nih.gov/16041840" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16041840</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_31">Yennurajalingam S, Frisbee-Hume S, Palmer JL, et al.: Reduction of cancer-related fatigue with dexamethasone: a double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol 31 (25): 3076-82, 2013. [<a href="https://pubmed.ncbi.nlm.nih.gov/23897970" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23897970</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_32">Cruciani RA, Zhang JJ, Manola J, et al.: L-carnitine supplementation for the management of fatigue in patients with cancer: an eastern cooperative oncology group phase III, randomized, double-blind, placebo-controlled trial. J Clin Oncol 30 (31): 3864-9, 2012. [<a href="/pmc/articles/PMC3478577/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3478577</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22987089" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 22987089</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_33">Barton DL, Soori GS, Bauer BA, et al.: Pilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation: NCCTG trial N03CA. Support Care Cancer 18 (2): 179-87, 2010. [<a href="/pmc/articles/PMC3911883/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3911883</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19415341" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19415341</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_34">Barton DL, Liu H, Dakhil SR, et al.: Wisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst 105 (16): 1230-8, 2013. [<a href="/pmc/articles/PMC3888141/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3888141</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23853057" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23853057</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_35">Segal R, Evans W, Johnson D, et al.: Structured exercise improves physical functioning in women with stages I and II breast cancer: results of a randomized controlled trial. J Clin Oncol 19 (3): 657-65, 2001. [<a href="https://pubmed.ncbi.nlm.nih.gov/11157015" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11157015</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_36">Milne HM, Wallman KE, Gordon S, et al.: Effects of a combined aerobic and resistance exercise program in breast cancer survivors: a randomized controlled trial. Breast Cancer Res Treat 108 (2): 279-88, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/17530428" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17530428</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_37">Courneya KS, Friedenreich CM, Sela RA, et al.: The group psychotherapy and home-based physical exercise (group-hope) trial in cancer survivors: physical fitness and quality of life outcomes. Psychooncology 12 (4): 357-74, 2003. [<a href="https://pubmed.ncbi.nlm.nih.gov/12748973" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12748973</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_38">Schneider CM, Hsieh CC, Sprod LK, et al.: Effects of supervised exercise training on cardiopulmonary function and fatigue in breast cancer survivors during and after treatment. Cancer 110 (4): 918-25, 2007. [<a href="https://pubmed.ncbi.nlm.nih.gov/17582616" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17582616</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_39">Friendenreich CM, Courneya KS: Exercise as rehabilitation for cancer patients. Clin J Sport Med 6 (4): 237-44, 1996. [<a href="https://pubmed.ncbi.nlm.nih.gov/8894336" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8894336</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_40">Mustian KM, Griggs JJ, Morrow GR, et al.: Exercise and side effects among 749 patients during and after treatment for cancer: a University of Rochester Cancer Center Community Clinical Oncology Program Study. Support Care Cancer 14 (7): 732-41, 2006. [<a href="https://pubmed.ncbi.nlm.nih.gov/16482444" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16482444</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_41">Winningham ML: Walking program for people with cancer. Getting started. Cancer Nurs 14 (5): 270-6, 1991. [<a href="https://pubmed.ncbi.nlm.nih.gov/1933847" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1933847</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_42">Galvão DA, Newton RU: Review of exercise intervention studies in cancer patients. J Clin Oncol 23 (4): 899-909, 2005. [<a href="https://pubmed.ncbi.nlm.nih.gov/15681536" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15681536</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_43">Cramp F, Daniel J: Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev (2): CD006145, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18425939" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18425939</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_44">Kangas M, Bovbjerg DH, Montgomery GH: Cancer-related fatigue: a systematic and meta-analytic review of non-pharmacological therapies for cancer patients. Psychol Bull 134 (5): 700-41, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18729569" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18729569</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_45">Berger AM, Abernethy AP, Atkinson A, et al.: Cancer-related fatigue. J Natl Compr Canc Netw 8 (8): 904-31, 2010. [<a href="https://pubmed.ncbi.nlm.nih.gov/20870636" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20870636</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_46">Jacobsen PB, Donovan KA, Vadaparampil ST, et al.: Systematic review and meta-analysis of psychological and activity-based interventions for cancer-related fatigue. Health Psychol 26 (6): 660-7, 2007. [<a href="/pmc/articles/PMC2398706/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2398706</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18020836" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18020836</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_47">Pickett M, Mock V, Ropka ME, et al.: Adherence to moderate-intensity exercise during breast cancer therapy. Cancer Pract 10 (6): 284-92, 2002 Nov-Dec. [<a href="https://pubmed.ncbi.nlm.nih.gov/12406050" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12406050</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_48">Dimeo FC, Stieglitz RD, Novelli-Fischer U, et al.: Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy. Cancer 85 (10): 2273-7, 1999. [<a href="https://pubmed.ncbi.nlm.nih.gov/10326708" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10326708</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_49">Mock V, Pickett M, Ropka ME, et al.: Fatigue and quality of life outcomes of exercise during cancer treatment. Cancer Pract 9 (3): 119-27, 2001 May-Jun. [<a href="https://pubmed.ncbi.nlm.nih.gov/11879296" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11879296</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_50">Mutrie N, Campbell AM, Whyte F, et al.: Benefits of supervised group exercise programme for women being treated for early stage breast cancer: pragmatic randomised controlled trial. BMJ 334 (7592): 517, 2007. [<a href="/pmc/articles/PMC1819494/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1819494</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17307761" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17307761</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_51">Matthews CE, Wilcox S, Hanby CL, et al.: Evaluation of a 12-week home-based walking intervention for breast cancer survivors. Support Care Cancer 15 (2): 203-11, 2007. [<a href="https://pubmed.ncbi.nlm.nih.gov/17001492" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17001492</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_52">Daley AJ, Crank H, Saxton JM, et al.: Randomized trial of exercise therapy in women treated for breast cancer. J Clin Oncol 25 (13): 1713-21, 2007. [<a href="https://pubmed.ncbi.nlm.nih.gov/17470863" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17470863</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_53">Alfano CM, Smith AW, Irwin ML, et al.: Physical activity, long-term symptoms, and physical health-related quality of life among breast cancer survivors: a prospective analysis. J Cancer Surviv 1 (2): 116-28, 2007. [<a href="/pmc/articles/PMC2996230/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2996230</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18648952" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18648952</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_54">Yoshioka H: Rehabilitation for the terminal cancer patient. Am J Phys Med Rehabil 73 (3): 199-206, 1994. [<a href="https://pubmed.ncbi.nlm.nih.gov/7515247" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7515247</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_55">Mock V, Frangakis C, Davidson NE, et al.: Exercise manages fatigue during breast cancer treatment: a randomized controlled trial. Psychooncology 14 (6): 464-77, 2005. [<a href="https://pubmed.ncbi.nlm.nih.gov/15484202" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15484202</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_56">Oh B, Butow P, Mullan B, et al.: Impact of medical Qigong on quality of life, fatigue, mood and inflammation in cancer patients: a randomized controlled trial. Ann Oncol 21 (3): 608-14, 2010. [<a href="/pmc/articles/PMC2826100/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2826100</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19880433" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19880433</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_57">Chen Z, Meng Z, Milbury K, et al.: Qigong improves quality of life in women undergoing radiotherapy for breast cancer: results of a randomized controlled trial. Cancer 119 (9): 1690-8, 2013. [<a href="/pmc/articles/PMC3852682/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC3852682</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23355182" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 23355182</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_58">Gielissen MF, Verhagen S, Witjes F, et al.: Effects of cognitive behavior therapy in severely fatigued disease-free cancer patients compared with patients waiting for cognitive behavior therapy: a randomized controlled trial. J Clin Oncol 24 (30): 4882-7, 2006. [<a href="https://pubmed.ncbi.nlm.nih.gov/17050873" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17050873</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_59">Nail LM, Jones LS, Greene D, et al.: Use and perceived efficacy of self-care activities in patients receiving chemotherapy. Oncol Nurs Forum 18 (5): 883-7, 1991. [<a href="https://pubmed.ncbi.nlm.nih.gov/1891417" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1891417</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_60">Dy SM, Lorenz KA, Naeim A, et al.: Evidence-based recommendations for cancer fatigue, anorexia, depression, and dyspnea. J Clin Oncol 26 (23): 3886-95, 2008. [<a href="https://pubmed.ncbi.nlm.nih.gov/18688057" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18688057</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_61">Winningham ML, Nail LM, Burke MB, et al.: Fatigue and the cancer experience: the state of the knowledge. Oncol Nurs Forum 21 (1): 23-36, 1994 Jan-Feb. [<a href="https://pubmed.ncbi.nlm.nih.gov/8139999" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8139999</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_62">Given B, Given CW, McCorkle R, et al.: Pain and fatigue management: results of a nursing randomized clinical trial. Oncol Nurs Forum 29 (6): 949-56, 2002. [<a href="https://pubmed.ncbi.nlm.nih.gov/12096292" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12096292</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_63">Ream E, Richardson A, Alexander-Dann C: Supportive intervention for fatigue in patients undergoing chemotherapy: a randomized controlled trial. J Pain Symptom Manage 31 (2): 148-61, 2006. [<a href="https://pubmed.ncbi.nlm.nih.gov/16488348" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16488348</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_83_64">Borneman T, Koczywas M, Sun VC, et al.: Reducing patient barriers to pain and fatigue management. J Pain Symptom Manage 39 (3): 486-501, 2010. [<a href="/pmc/articles/PMC2844345/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2844345</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20303026" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 20303026</span></a>]</div></li></ol></div></div><div id="CDR0000062734__104"><h2 id="_CDR0000062734__104_">Posttreatment Considerations</h2><p id="CDR0000062734__105">This posttreatment section has been especially prepared for those individuals
|
|
with cancer who have been off all antineoplastic therapy for at least
|
|
6 months. The rationale for creating a separate section is twofold. First,
|
|
the etiology of problems is different for individuals undergoing treatment
|
|
versus those who are no longer undergoing therapy. Second, intervention
|
|
strategies and information can be better tailored so that there will be a
|
|
greater likelihood of meeting the needs of these two distinct populations.</p><p id="CDR0000062734__106">Fatigue is a separate and distinct problem for individuals after treatment is
|
|
completed. Many theories have been proposed to explain the etiology of fatigue
|
|
in the patient undergoing treatment and to explain the impact of that treatment
|
|
on quality of life. Many of these theories, however, do not apply to the posttreatment population. Nonetheless, fatigue continues to be a major issue for
|
|
individuals who are no longer undergoing therapy and who are considered to be
|
|
disease free.</p><p id="CDR0000062734__107">There is evidence that fatigue significantly affects the quality of life of
|
|
cancer survivors. The experience of fatigue in cancer survivors is quite
|
|
similar to the experience of patients with chronic fatigue syndrome in the
|
|
general medical setting.[<a class="bk_pop" href="#CDR0000062734_rl_104_1">1</a>] Few studies have been done that indicate the
|
|
impact of fatigue on quality of life, but some examples follow:</p><ul id="CDR0000062734__108"><li class="half_rhythm"><div>In cancer survivors who had bone marrow transplants, 50% of 29 survivors
|
|
reported moderate-to-severe fatigue more than 1 year after transplant.
|
|
Fatigue was one of the three most negative items studied and had an impact
|
|
on quality of life more than any other physical problem.[<a class="bk_pop" href="#CDR0000062734_rl_104_2">2</a>]</div></li><li class="half_rhythm"><div>In patients who had bone marrow transplants, 56% of 125 patients reported
|
|
ongoing fatigue 6 to 18 years after transplant.[<a class="bk_pop" href="#CDR0000062734_rl_104_3">3</a>]
|
|
</div></li><li class="half_rhythm"><div>Of 687 posttreatment survivors of various forms of cancer evaluated for
|
|
quality-of-life issues, fatigue was one of the three most negative items
|
|
affecting quality of life.[<a class="bk_pop" href="#CDR0000062734_rl_104_4">4</a>]</div></li><li class="half_rhythm"><div>Of 90 patients with a diagnosis of Hodgkin lymphoma or non-Hodgkin
|
|
lymphoma, 30 reported a lack of energy at a median of 32 months after
|
|
diagnosis.[<a class="bk_pop" href="#CDR0000062734_rl_104_5">5</a>]</div></li><li class="half_rhythm"><div>Of 403 individuals with Hodgkin lymphoma, 37% reported their energy levels
|
|
had not returned to levels that satisfied them even after a median of 9
|
|
years posttreatment.[<a class="bk_pop" href="#CDR0000062734_rl_104_6">6</a>]</div></li><li class="half_rhythm"><div>In Hodgkin lymphoma survivors, 26% had persistent fatigue 6 months after
|
|
treatment with 50% associated with psychological distress. Increasing age and
|
|
no prior psychological symptoms predicted fatigue “caseness.”[<a class="bk_pop" href="#CDR0000062734_rl_104_7">7</a>]</div></li><li class="half_rhythm"><div>Of 162 women treated with radiation for breast cancer and 173 women treated
|
|
with chemotherapy for breast cancer, 75% and 61%, respectively,
|
|
described decreased stamina 2 to 10 years after the completion of
|
|
treatment.[<a class="bk_pop" href="#CDR0000062734_rl_104_8">8</a>] In a separate cross-sectional survey of women who completed therapy for breast cancer by a mean of 29 months prior to the survey, 38% had severe fatigue compared with only 11% of matched controls.[<a class="bk_pop" href="#CDR0000062734_rl_104_9">9</a>]</div></li><li class="half_rhythm"><div>Fatigue has been reported in women survivors of autologous bone marrow
|
|
transplantation and high-dose chemotherapy treatment for lymphomas 4
|
|
to 10 years posttreatment.[<a class="bk_pop" href="#CDR0000062734_rl_104_10">10</a>]</div></li><li class="half_rhythm"><div>Almost one-third of breast cancer survivors at 10 years posttreatment reported significant fatigue.[<a class="bk_pop" href="#CDR0000062734_rl_104_11">11</a>]</div></li></ul><p id="CDR0000062734__109">Although many studies document the incidence of fatigue in those who are no
|
|
longer undergoing cancer treatment, the specific mechanism of fatigue remains
|
|
unknown. Because fatigue is a multifaceted problem, determining its etiology
|
|
is difficult.</p><p id="CDR0000062734__110">The information available regarding fatigue in survivors of childhood cancer is
|
|
from the literature describing the physiologic and cognitive effects following
|
|
treatment. In one study, cognitive outcomes were evaluated in children 3 to 4
|
|
years after diagnosis of brain tumors. Fatigue was a factor in poor school
|
|
performance.[<a class="bk_pop" href="#CDR0000062734_rl_104_12">12</a>]</p><p id="CDR0000062734__111">In another study, survivors of acute lymphoblastic leukemia who were evaluated
|
|
for cognitive deficits after treatment were noted to have a typical fatigue
|
|
effect. This was thought to be a factor in the variability of their test
|
|
scores.[<a class="bk_pop" href="#CDR0000062734_rl_104_13">13</a>] Anecdotally, individuals who have received chest and total-body
|
|
irradiation complain of fatigue, with an increased sleep requirement.</p><p id="CDR0000062734__112">People who are successfully treated for cancer are at risk for a variety of
|
|
organ-specific complications that are secondary to their treatment.[<a class="bk_pop" href="#CDR0000062734_rl_104_14">14</a>] Fatigue in
|
|
the posttreatment population underscores the importance of follow-up care.
|
|
The persistence of fatigue following cancer treatment requires a thorough
|
|
evaluation to rule out contributing physiologic conditions.</p><div id="CDR0000062734_rl_104"><h3>References</h3><ol><li><div class="bk_ref" id="CDR0000062734_rl_104_1">Servaes P, van der Werf S, Prins J, et al.: Fatigue in disease-free cancer patients compared with fatigue in patients with chronic fatigue syndrome. Support Care Cancer 9 (1): 11-7, 2001. [<a href="https://pubmed.ncbi.nlm.nih.gov/11147137" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11147137</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_104_2">Whedon M, Stearns D, Mills LE: Quality of life of long-term adult survivors of autologous bone marrow transplantation. Oncol Nurs Forum 22 (10): 1527-35; discussion 1535-7, 1995 Nov-Dec. [<a href="https://pubmed.ncbi.nlm.nih.gov/8577621" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8577621</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_104_3">Bush NE, Haberman M, Donaldson G, et al.: Quality of life of 125 adults surviving 6-18 years after bone marrow transplantation. Soc Sci Med 40 (4): 479-90, 1995. [<a href="https://pubmed.ncbi.nlm.nih.gov/7725122" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 7725122</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_104_4">Ferrell BR, Grant M, Dean GE, et al.: Bone tired: the experience of fatigue and its impact on quality of life. Oncol Nurs Forum 23 (10): 1539-47, 1996.</div></li><li><div class="bk_ref" id="CDR0000062734_rl_104_5">Devlen J, Maguire P, Phillips P, et al.: Psychological problems associated with diagnosis and treatment of lymphomas. II: Prospective study. Br Med J (Clin Res Ed) 295 (6604): 955-7, 1987. [<a href="/pmc/articles/PMC1248003/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1248003</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/3119124" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3119124</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_104_6">Fobair P, Hoppe RT, Bloom J, et al.: Psychosocial problems among survivors of Hodgkin's disease. J Clin Oncol 4 (5): 805-14, 1986. [<a href="https://pubmed.ncbi.nlm.nih.gov/3486256" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3486256</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_104_7">Loge JH, Abrahamsen AF, Ekeberg, et al.: Fatigue and psychiatric morbidity among Hodgkin's disease survivors. J Pain Symptom Manage 19 (2): 91-9, 2000. [<a href="https://pubmed.ncbi.nlm.nih.gov/10699536" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10699536</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_104_8">Berglund G, Bolund C, Fornander T, et al.: Late effects of adjuvant chemotherapy and postoperative radiotherapy on quality of life among breast cancer patients. Eur J Cancer 27 (9): 1075-81, 1991. [<a href="https://pubmed.ncbi.nlm.nih.gov/1683557" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1683557</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_104_9">Servaes P, Verhagen S, Bleijenberg G: Determinants of chronic fatigue in disease-free breast cancer patients: a cross-sectional study. Ann Oncol 13 (4): 589-98, 2002. [<a href="https://pubmed.ncbi.nlm.nih.gov/12056710" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12056710</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_104_10">Knobel H, Loge JH, Nordøy T, et al.: High level of fatigue in lymphoma patients treated with high dose therapy. J Pain Symptom Manage 19 (6): 446-56, 2000. [<a href="https://pubmed.ncbi.nlm.nih.gov/10908825" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 10908825</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_104_11">Bower JE, Ganz PA, Desmond KA, et al.: Fatigue in long-term breast carcinoma survivors: a longitudinal investigation. Cancer 106 (4): 751-8, 2006. [<a href="https://pubmed.ncbi.nlm.nih.gov/16400678" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16400678</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_104_12">Radcliffe J, Packer RJ, Atkins TE, et al.: Three- and four-year cognitive outcome in children with noncortical brain tumors treated with whole-brain radiotherapy. Ann Neurol 32 (4): 551-4, 1992. [<a href="https://pubmed.ncbi.nlm.nih.gov/1456739" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 1456739</span></a>]</div></li><li><div class="bk_ref" id="CDR0000062734_rl_104_13">Brouwers P: Neuropsychological abilities of long-term survivors of childhood leukemia. In: Aaronsen NK, Beckmann J, eds.: The Quality of Life of Cancer Patients. New York: Raven Press, 1987, pp 153-65.</div></li><li><div class="bk_ref" id="CDR0000062734_rl_104_14">Baker F, Denniston M, Smith T, et al.: Adult cancer survivors: how are they faring? Cancer 104 (11 Suppl): 2565-76, 2005. [<a href="https://pubmed.ncbi.nlm.nih.gov/16258929" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 16258929</span></a>]</div></li></ol></div></div><div id="CDR0000062734__125"><h2 id="_CDR0000062734__125_">Changes to This Summary (01/13/2017)</h2><p id="CDR0000062734__135">The PDQ cancer information summaries are reviewed regularly and updated as new information becomes available. This section describes the latest changes made to this summary as of the date above.</p><p id="CDR0000062734__352">Editorial changes were made to this summary.</p><p id="CDR0000062734__disclaimerHP_3">This summary is written and maintained by the <a href="http://www.cancer.gov/publications/pdq/editorial-boards/supportive-care" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PDQ Supportive and Palliative Care Editorial Board</a>, which is
|
|
editorially independent of NCI. The summary reflects an independent review of
|
|
the literature and does not represent a policy statement of NCI or NIH. More
|
|
information about summary policies and the role of the PDQ Editorial Boards in
|
|
maintaining the PDQ summaries can be found on the <a href="#CDR0000062734__AboutThis_1">About This PDQ Summary</a> and <a href="http://www.cancer.gov/publications/pdq" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PDQ® - NCI's Comprehensive Cancer Database</a> pages.
|
|
</p></div><div id="CDR0000062734__AboutThis_1"><h2 id="_CDR0000062734__AboutThis_1_">About This PDQ Summary</h2><div id="CDR0000062734__AboutThis_2"><h3>Purpose of This Summary</h3><p id="CDR0000062734__AboutThis_3">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the pathophysiology and treatment of fatigue. It is intended as a resource to inform and assist clinicians who care for cancer patients. It does not provide formal guidelines or recommendations for making health care decisions.</p></div><div id="CDR0000062734__AboutThis_4"><h3>Reviewers and Updates</h3><p id="CDR0000062734__AboutThis_5">This summary is reviewed regularly and updated as necessary by the <a href="http://www.cancer.gov/publications/pdq/editorial-boards/supportive-care" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PDQ Supportive and Palliative Care Editorial Board</a>, which is editorially independent of the National Cancer Institute (NCI). The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</p><p id="CDR0000062734__AboutThis_22"> Board members review recently published articles each month to determine whether an article should:</p><ul id="CDR0000062734__AboutThis_6"><li class="half_rhythm"><div>be discussed at a meeting,</div></li><li class="half_rhythm"><div>be cited with text, or</div></li><li class="half_rhythm"><div>replace or update an existing article that is already cited.</div></li></ul><p id="CDR0000062734__AboutThis_7">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in the published articles and determine how the article should be included in the summary.</p><p>The lead reviewers for Fatigue are:</p><ul><li class="half_rhythm"><div>Andrea Barsevick, PhD (Thomas Jefferson University)</div></li><li class="half_rhythm"><div>Jayesh Kamath, MD, PhD (University of Connecticut Health Center)</div></li><li class="half_rhythm"><div>Lillian M. Nail, PhD, RN, FAAN, CNS (Oregon Health & Science University Cancer Institute)</div></li></ul><p id="CDR0000062734__AboutThis_9">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <a href="https://www.cancer.gov/contact/email-us" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Email Us</a>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</p></div><div id="CDR0000062734__AboutThis_10"><h3>Levels of Evidence</h3><p id="CDR0000062734__AboutThis_11">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Supportive and Palliative Care Editorial Board uses a <a href="/books/n/pdqcis/CDR0000660468/">formal evidence ranking system</a> in developing its level-of-evidence designations.</p></div><div id="CDR0000062734__AboutThis_12"><h3>Permission to Use This Summary</h3><p id="CDR0000062734__AboutThis_13">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as “NCI’s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].”</p><p id="CDR0000062734__AboutThis_14">The preferred citation for this PDQ summary is:</p><p id="CDR0000062734__AboutThis_15">PDQ® Supportive and Palliative Care Editorial Board. PDQ Fatigue. Bethesda, MD: National Cancer Institute. Updated <MM/DD/YYYY>. Available at: <a href="https://www.cancer.gov/about-cancer/treatment/side-effects/fatigue/fatigue-hp-pdq" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">https://www.cancer.gov/about-cancer/treatment/side-effects/fatigue/fatigue-hp-pdq</a>. Accessed <MM/DD/YYYY>. [PMID: 26389484]</p><p id="CDR0000062734__AboutThis_16">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <a href="https://visualsonline.cancer.gov/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Visuals Online</a>, a collection of over 2,000 scientific images.
|
|
</p></div><div id="CDR0000062734__AboutThis_17"><h3>Disclaimer</h3><p id="CDR0000062734__AboutThis_19">The information in these summaries should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <a href="https://www.cancer.gov/about-cancer/managing-care" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Managing Cancer Care</a> page.</p></div><div id="CDR0000062734__AboutThis_20"><h3>Contact Us</h3><p id="CDR0000062734__AboutThis_21">More information about contacting us or receiving help with the Cancer.gov website can be found on our <a href="https://www.cancer.gov/contact" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Contact Us for Help</a> page. Questions can also be submitted to Cancer.gov through the website’s <a href="https://www.cancer.gov/contact/email-us" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Email Us</a>.</p></div></div></div></div>
|
|
<div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK66049</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/26389484" title="PubMed record of this page" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">26389484</a></span></div></div></div>
|
|
|
|
</div>
|
|
|
|
<!-- Custom content below content -->
|
|
<div class="col4">
|
|
|
|
</div>
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<!-- Custom contetnt below bottom nav -->
|
|
<div class="col5">
|
|
|
|
</div>
|
|
</div>
|
|
|
|
<div id="rightcolumn" class="four_col col last">
|
|
<!-- Custom content above discovery portlets -->
|
|
<div class="col6">
|
|
<div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK66049&db=books">Share</a></div>
|
|
|
|
</div>
|
|
<div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK66049.2/?report=reader">PubReader</a></li><li><a href="/books/NBK66049.2/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK66049" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK66049" style="display:none" title="Cite this Page"><div class="bk_tt">PDQ Supportive and Palliative Care Editorial Board. Fatigue (PDQ®): Health Professional Version. 2017 Jan 13. In: PDQ Cancer Information Summaries [Internet]. Bethesda (MD): National Cancer Institute (US); 2002-. <span class="bk_cite_avail"></span></div></div></li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Version History</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter shutter_closed" title="Show/hide content" remembercollapsed="true" pgsec_name="version_history" id="Shutter"></a></div><div class="portlet_content" style="display: none;"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><span class="bk_col_itm"><a href="/books/NBK66049.12/">NBK66049.12</a></span> November 6, 2024</li><li><span class="bk_col_itm"><a href="/books/NBK66049.11/">NBK66049.11</a></span> July 17, 2024</li><li><span class="bk_col_itm"><a href="/books/NBK66049.10/">NBK66049.10</a></span> August 31, 2023</li><li><span class="bk_col_itm"><a href="/books/NBK66049.9/">NBK66049.9</a></span> July 13, 2023</li><li><span class="bk_col_itm"><a href="/books/NBK66049.8/">NBK66049.8</a></span> June 23, 2023</li><li><span class="bk_col_itm"><a href="/books/NBK66049.7/">NBK66049.7</a></span> September 1, 2022</li><li><span class="bk_col_itm"><a href="/books/NBK66049.6/">NBK66049.6</a></span> April 20, 2022</li><li><span class="bk_col_itm"><a href="/books/NBK66049.5/">NBK66049.5</a></span> November 17, 2021</li><li><span class="bk_col_itm"><a href="/books/NBK66049.4/">NBK66049.4</a></span> January 28, 2021</li><li><span class="bk_col_itm"><a href="/books/NBK66049.3/">NBK66049.3</a></span> June 29, 2017</li><li><span class="bk_col_itm">NBK66049.2</span> January 13, 2017 (Displayed Version)</li><li><span class="bk_col_itm"><a href="/books/NBK66049.1/">NBK66049.1</a></span> August 28, 2014</li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this Page</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#CDR0000062734__1" ref="log$=inpage&link_id=inpage">Overview</a></li><li><a href="#CDR0000062734__7" ref="log$=inpage&link_id=inpage">Pathogenesis of Fatigue</a></li><li><a href="#CDR0000062734__12" ref="log$=inpage&link_id=inpage">Contributing Factors</a></li><li><a href="#CDR0000062734__35" ref="log$=inpage&link_id=inpage">Assessment</a></li><li><a href="#CDR0000062734__83" ref="log$=inpage&link_id=inpage">Intervention</a></li><li><a href="#CDR0000062734__104" ref="log$=inpage&link_id=inpage">Posttreatment Considerations</a></li><li><a href="#CDR0000062734__125" ref="log$=inpage&link_id=inpage">Changes to This Summary (01/13/2017)</a></li><li><a href="#CDR0000062734__AboutThis_1" ref="log$=inpage&link_id=inpage">About This PDQ Summary</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related publications</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK65818/">Patient Version</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&DbFrom=books&Cmd=Link&LinkName=books_pmc_refs&IdsFromResult=2822426" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&DbFrom=books&Cmd=Link&LinkName=books_pubmed_refs&IdsFromResult=2822426" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26389173" ref="ordinalpos=1&linkpos=1&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Delirium (PDQ®): Health Professional Version.</a><span class="source">[PDQ Cancer Information Summari...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Delirium (PDQ®): Health Professional Version.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">PDQ Supportive and Palliative Care Editorial Board. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PDQ Cancer Information Summaries. 2002</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/39012991" ref="ordinalpos=1&linkpos=2&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Symptom Clusters in Cancer (PDQ®): Health Professional Version.</a><span class="source">[PDQ Cancer Information Summari...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Symptom Clusters in Cancer (PDQ®): Health Professional Version.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">PDQ Supportive and Palliative Care Editorial Board. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PDQ Cancer Information Summaries. 2002</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26389413" ref="ordinalpos=1&linkpos=3&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Levels of Evidence for Supportive and Palliative Care Studies (PDQ®): Health Professional Version.</a><span class="source">[PDQ Cancer Information Summari...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Levels of Evidence for Supportive and Palliative Care Studies (PDQ®): Health Professional Version.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">PDQ Supportive and Palliative Care Editorial Board. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PDQ Cancer Information Summaries. 2002</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26389436" ref="ordinalpos=1&linkpos=4&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spirituality in Cancer Care (PDQ®): Health Professional Version.</a><span class="source">[PDQ Cancer Information Summari...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Spirituality in Cancer Care (PDQ®): Health Professional Version.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">PDQ Supportive and Palliative Care Editorial Board. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PDQ Cancer Information Summaries. 2002</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/26389370" ref="ordinalpos=1&linkpos=5&log$=relatedreviews&logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Communication in Cancer Care (PDQ®): Health Professional Version.</a><span class="source">[PDQ Cancer Information Summari...]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Communication in Cancer Care (PDQ®): Health Professional Version.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">PDQ Supportive and Palliative Care Editorial Board. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">PDQ Cancer Information Summaries. 2002</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&cmd=link&linkname=pubmed_pubmed_reviews&uid=26389484" ref="ordinalpos=1&log$=relatedreviews_seeall&logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&cmd=link&linkname=pubmed_pubmed&uid=26389484" ref="ordinalpos=1&log$=relatedarticles_seeall&logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=67c97e3dab82281a807b96d4">Fatigue (PDQ®) - PDQ Cancer Information Summaries</a><div class="ralinkpop offscreen_noflow">Fatigue (PDQ®) - PDQ Cancer Information Summaries<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&linkpos=2" href="/portal/utils/pageresolver.fcgi?recordid=67c97e04a68b6b5afcb06134">Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®) - PDQ Cancer Information...</a><div class="ralinkpop offscreen_noflow">Childhood Acute Lymphoblastic Leukemia Treatment (PDQ®) - PDQ Cancer Information Summaries<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
|
|
|
|
<!-- Custom content below discovery portlets -->
|
|
<div class="col7">
|
|
|
|
</div>
|
|
</div>
|
|
</div>
|
|
|
|
<!-- Custom content after all -->
|
|
<div class="col8">
|
|
|
|
</div>
|
|
<div class="col9">
|
|
|
|
</div>
|
|
|
|
<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
|
|
<script type="text/javascript">
|
|
(function($){
|
|
$('.skiplink').each(function(i, item){
|
|
var href = $($(item).attr('href'));
|
|
href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
|
|
$(item).on('click', function(event){
|
|
event.preventDefault();
|
|
$.scrollTo(href, 0, {
|
|
onAfter: function(){
|
|
href.focus();
|
|
}
|
|
});
|
|
});
|
|
});
|
|
})(jQuery);
|
|
</script>
|
|
</div>
|
|
<div class="bottom">
|
|
|
|
<div id="NCBIFooter_dynamic">
|
|
<!--<component id="Breadcrumbs" label="breadcrumbs"/>
|
|
<component id="Breadcrumbs" label="helpdesk"/>-->
|
|
|
|
</div>
|
|
|
|
<div class="footer" id="footer">
|
|
<section class="icon-section">
|
|
<div id="icon-section-header" class="icon-section_header">Follow NCBI</div>
|
|
<div class="grid-container container">
|
|
<div class="icon-section_container">
|
|
<a class="footer-icon" id="footer_twitter" href="https://twitter.com/ncbi" aria-label="Twitter"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
|
<defs>
|
|
<style>
|
|
.cls-11 {
|
|
fill: #737373;
|
|
}
|
|
</style>
|
|
</defs>
|
|
<title>Twitter</title>
|
|
<path class="cls-11" d="M250.11,105.48c-7,3.14-13,3.25-19.27.14,8.12-4.86,8.49-8.27,11.43-17.46a78.8,78.8,0,0,1-25,9.55,39.35,39.35,0,0,0-67,35.85,111.6,111.6,0,0,1-81-41.08A39.37,39.37,0,0,0,81.47,145a39.08,39.08,0,0,1-17.8-4.92c0,.17,0,.33,0,.5a39.32,39.32,0,0,0,31.53,38.54,39.26,39.26,0,0,1-17.75.68,39.37,39.37,0,0,0,36.72,27.3A79.07,79.07,0,0,1,56,223.34,111.31,111.31,0,0,0,116.22,241c72.3,0,111.83-59.9,111.83-111.84,0-1.71,0-3.4-.1-5.09C235.62,118.54,244.84,113.37,250.11,105.48Z">
|
|
</path>
|
|
</svg></a>
|
|
<a class="footer-icon" id="footer_facebook" href="https://www.facebook.com/ncbi.nlm" aria-label="Facebook"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
|
<title>Facebook</title>
|
|
<path class="cls-11" d="M210.5,115.12H171.74V97.82c0-8.14,5.39-10,9.19-10h27.14V52l-39.32-.12c-35.66,0-42.42,26.68-42.42,43.77v19.48H99.09v36.32h27.24v109h45.41v-109h35Z">
|
|
</path>
|
|
</svg></a>
|
|
<a class="footer-icon" id="footer_linkedin" href="https://www.linkedin.com/company/ncbinlm" aria-label="LinkedIn"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
|
<title>LinkedIn</title>
|
|
<path class="cls-11" d="M101.64,243.37H57.79v-114h43.85Zm-22-131.54h-.26c-13.25,0-21.82-10.36-21.82-21.76,0-11.65,8.84-21.15,22.33-21.15S101.7,78.72,102,90.38C102,101.77,93.4,111.83,79.63,111.83Zm100.93,52.61A17.54,17.54,0,0,0,163,182v61.39H119.18s.51-105.23,0-114H163v13a54.33,54.33,0,0,1,34.54-12.66c26,0,44.39,18.8,44.39,55.29v58.35H198.1V182A17.54,17.54,0,0,0,180.56,164.44Z">
|
|
</path>
|
|
</svg></a>
|
|
<a class="footer-icon" id="footer_github" href="https://github.com/ncbi" aria-label="GitHub"><svg xmlns="http://www.w3.org/2000/svg" data-name="Layer 1" viewBox="0 0 300 300">
|
|
<defs>
|
|
<style>
|
|
.cls-11,
|
|
.cls-12 {
|
|
fill: #737373;
|
|
}
|
|
|
|
.cls-11 {
|
|
fill-rule: evenodd;
|
|
}
|
|
</style>
|
|
</defs>
|
|
<title>GitHub</title>
|
|
<path class="cls-11" d="M151.36,47.28a105.76,105.76,0,0,0-33.43,206.1c5.28,1,7.22-2.3,7.22-5.09,0-2.52-.09-10.85-.14-19.69-29.42,6.4-35.63-12.48-35.63-12.48-4.81-12.22-11.74-15.47-11.74-15.47-9.59-6.56.73-6.43.73-6.43,10.61.75,16.21,10.9,16.21,10.9,9.43,16.17,24.73,11.49,30.77,8.79,1-6.83,3.69-11.5,6.71-14.14C108.57,197.1,83.88,188,83.88,147.51a40.92,40.92,0,0,1,10.9-28.39c-1.1-2.66-4.72-13.42,1-28,0,0,8.88-2.84,29.09,10.84a100.26,100.26,0,0,1,53,0C198,88.3,206.9,91.14,206.9,91.14c5.76,14.56,2.14,25.32,1,28a40.87,40.87,0,0,1,10.89,28.39c0,40.62-24.74,49.56-48.29,52.18,3.79,3.28,7.17,9.71,7.17,19.58,0,14.15-.12,25.54-.12,29,0,2.82,1.9,6.11,7.26,5.07A105.76,105.76,0,0,0,151.36,47.28Z">
|
|
</path>
|
|
<path class="cls-12" d="M85.66,199.12c-.23.52-1.06.68-1.81.32s-1.2-1.06-.95-1.59,1.06-.69,1.82-.33,1.21,1.07.94,1.6Zm-1.3-1">
|
|
</path>
|
|
<path class="cls-12" d="M90,203.89c-.51.47-1.49.25-2.16-.49a1.61,1.61,0,0,1-.31-2.19c.52-.47,1.47-.25,2.17.49s.82,1.72.3,2.19Zm-1-1.08">
|
|
</path>
|
|
<path class="cls-12" d="M94.12,210c-.65.46-1.71,0-2.37-.91s-.64-2.07,0-2.52,1.7,0,2.36.89.65,2.08,0,2.54Zm0,0"></path>
|
|
<path class="cls-12" d="M99.83,215.87c-.58.64-1.82.47-2.72-.41s-1.18-2.06-.6-2.7,1.83-.46,2.74.41,1.2,2.07.58,2.7Zm0,0">
|
|
</path>
|
|
<path class="cls-12" d="M107.71,219.29c-.26.82-1.45,1.2-2.64.85s-2-1.34-1.74-2.17,1.44-1.23,2.65-.85,2,1.32,1.73,2.17Zm0,0">
|
|
</path>
|
|
<path class="cls-12" d="M116.36,219.92c0,.87-1,1.59-2.24,1.61s-2.29-.68-2.3-1.54,1-1.59,2.26-1.61,2.28.67,2.28,1.54Zm0,0">
|
|
</path>
|
|
<path class="cls-12" d="M124.42,218.55c.15.85-.73,1.72-2,1.95s-2.37-.3-2.52-1.14.73-1.75,2-2,2.37.29,2.53,1.16Zm0,0"></path>
|
|
</svg></a>
|
|
<a class="footer-icon" id="footer_blog" href="https://ncbiinsights.ncbi.nlm.nih.gov/" aria-label="Blog">
|
|
<svg xmlns="http://www.w3.org/2000/svg" id="Layer_1" data-name="Layer 1" viewBox="0 0 40 40">
|
|
<defs><style>.cls-1{fill:#737373;}</style></defs>
|
|
<title>NCBI Insights Blog</title>
|
|
<path class="cls-1" d="M14,30a4,4,0,1,1-4-4,4,4,0,0,1,4,4Zm11,3A19,19,0,0,0,7.05,15a1,1,0,0,0-1,1v3a1,1,0,0,0,.93,1A14,14,0,0,1,20,33.07,1,1,0,0,0,21,34h3a1,1,0,0,0,1-1Zm9,0A28,28,0,0,0,7,6,1,1,0,0,0,6,7v3a1,1,0,0,0,1,1A23,23,0,0,1,29,33a1,1,0,0,0,1,1h3A1,1,0,0,0,34,33Z"></path>
|
|
</svg>
|
|
</a>
|
|
</div>
|
|
</div>
|
|
</section>
|
|
|
|
<section class="container-fluid bg-primary">
|
|
<div class="container pt-5">
|
|
<div class="row mt-3">
|
|
<div class="col-lg-3 col-12">
|
|
<p><a class="text-white" href="https://www.nlm.nih.gov/socialmedia/index.html">Connect with NLM</a></p>
|
|
<ul class="list-inline social_media">
|
|
<li class="list-inline-item"><a href="https://twitter.com/NLM_NIH" aria-label="Twitter" target="_blank" rel="noopener noreferrer"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" version="1.1" x="0px" y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
|
|
<style type="text/css">
|
|
.st20 {
|
|
fill: #FFFFFF;
|
|
}
|
|
|
|
.st30 {
|
|
fill: none;
|
|
stroke: #FFFFFF;
|
|
stroke-width: 8;
|
|
stroke-miterlimit: 10;
|
|
}
|
|
</style>
|
|
<title>Twitter</title>
|
|
<g>
|
|
<g>
|
|
<g>
|
|
<path class="st20" d="M192.9,88.1c-5,2.2-9.2,2.3-13.6,0.1c5.7-3.4,6-5.8,8.1-12.3c-5.4,3.2-11.4,5.5-17.6,6.7 c-10.5-11.2-28.1-11.7-39.2-1.2c-7.2,6.8-10.2,16.9-8,26.5c-22.3-1.1-43.1-11.7-57.2-29C58,91.6,61.8,107.9,74,116 c-4.4-0.1-8.7-1.3-12.6-3.4c0,0.1,0,0.2,0,0.4c0,13.2,9.3,24.6,22.3,27.2c-4.1,1.1-8.4,1.3-12.5,0.5c3.6,11.3,14,19,25.9,19.3 c-11.6,9.1-26.4,13.2-41.1,11.5c12.7,8.1,27.4,12.5,42.5,12.5c51,0,78.9-42.2,78.9-78.9c0-1.2,0-2.4-0.1-3.6 C182.7,97.4,189.2,93.7,192.9,88.1z"></path>
|
|
</g>
|
|
</g>
|
|
<circle class="st30" cx="124.4" cy="128.8" r="108.2"></circle>
|
|
</g>
|
|
</svg></a></li>
|
|
<li class="list-inline-item"><a href="https://www.facebook.com/nationallibraryofmedicine" aria-label="Facebook" rel="noopener noreferrer" target="_blank">
|
|
<svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" version="1.1" x="0px" y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
|
|
<style type="text/css">
|
|
.st10 {
|
|
fill: #FFFFFF;
|
|
}
|
|
|
|
.st110 {
|
|
fill: none;
|
|
stroke: #FFFFFF;
|
|
stroke-width: 8;
|
|
stroke-miterlimit: 10;
|
|
}
|
|
</style>
|
|
<title>Facebook</title>
|
|
<g>
|
|
<g>
|
|
<path class="st10" d="M159,99.1h-24V88.4c0-5,3.3-6.2,5.7-6.2h16.8V60l-24.4-0.1c-22.1,0-26.2,16.5-26.2,27.1v12.1H90v22.5h16.9 v67.5H135v-67.5h21.7L159,99.1z"></path>
|
|
</g>
|
|
</g>
|
|
<circle class="st110" cx="123.6" cy="123.2" r="108.2"></circle>
|
|
</svg>
|
|
</a></li>
|
|
<li class="list-inline-item"><a href="https://www.youtube.com/user/NLMNIH" aria-label="Youtube" target="_blank" rel="noopener noreferrer"><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" version="1.1" x="0px" y="0px" viewBox="0 0 249 249" style="enable-background:new 0 0 249 249;" xml:space="preserve">
|
|
<title>Youtube</title>
|
|
<style type="text/css">
|
|
.st4 {
|
|
fill: none;
|
|
stroke: #FFFFFF;
|
|
stroke-width: 8;
|
|
stroke-miterlimit: 10;
|
|
}
|
|
|
|
.st5 {
|
|
fill: #FFFFFF;
|
|
}
|
|
</style>
|
|
<circle class="st4" cx="124.2" cy="123.4" r="108.2"></circle>
|
|
<g transform="translate(0,-952.36218)">
|
|
<path class="st5" d="M88.4,1037.4c-10.4,0-18.7,8.3-18.7,18.7v40.1c0,10.4,8.3,18.7,18.7,18.7h72.1c10.4,0,18.7-8.3,18.7-18.7 v-40.1c0-10.4-8.3-18.7-18.7-18.7H88.4z M115.2,1058.8l29.4,17.4l-29.4,17.4V1058.8z"></path>
|
|
</g>
|
|
</svg></a></li>
|
|
</ul>
|
|
</div>
|
|
<div class="col-lg-3 col-12">
|
|
<p class="address_footer text-white">National Library of Medicine<br />
|
|
<a href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/@38.9959508,-77.101021,17z/data=!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb:0x19156f88b27635b8!8m2!3d38.9959508!4d-77.0988323" class="text-white" target="_blank" rel="noopener noreferrer">8600 Rockville Pike<br />
|
|
Bethesda, MD 20894</a></p>
|
|
</div>
|
|
<div class="col-lg-3 col-12 centered-lg">
|
|
<p><a href="https://www.nlm.nih.gov/web_policies.html" class="text-white">Web Policies</a><br />
|
|
<a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="text-white">FOIA</a><br />
|
|
<a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="text-white" id="vdp">HHS Vulnerability Disclosure</a></p>
|
|
</div>
|
|
<div class="col-lg-3 col-12 centered-lg">
|
|
<p><a class="supportLink text-white" href="https://support.nlm.nih.gov/">Help</a><br />
|
|
<a href="https://www.nlm.nih.gov/accessibility.html" class="text-white">Accessibility</a><br />
|
|
<a href="https://www.nlm.nih.gov/careers/careers.html" class="text-white">Careers</a></p>
|
|
</div>
|
|
</div>
|
|
<div class="row">
|
|
<div class="col-lg-12 centered-lg">
|
|
<nav class="bottom-links">
|
|
<ul class="mt-3">
|
|
<li>
|
|
<a class="text-white" href="//www.nlm.nih.gov/">NLM</a>
|
|
</li>
|
|
<li>
|
|
<a class="text-white" href="https://www.nih.gov/">NIH</a>
|
|
</li>
|
|
<li>
|
|
<a class="text-white" href="https://www.hhs.gov/">HHS</a>
|
|
</li>
|
|
<li>
|
|
<a class="text-white" href="https://www.usa.gov/">USA.gov</a>
|
|
</li>
|
|
</ul>
|
|
</nav>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
</section>
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
|
|
</div>
|
|
</div>
|
|
</div>
|
|
<!--/.page-->
|
|
</div>
|
|
<!--/.wrap-->
|
|
</div><!-- /.twelve_col -->
|
|
</div>
|
|
<!-- /.grid -->
|
|
|
|
<span class="PAFAppResources"></span>
|
|
|
|
<!-- BESelector tab -->
|
|
|
|
|
|
|
|
<noscript><img alt="statistics" src="/stat?jsdisabled=true&ncbi_db=books&ncbi_pdid=book-part&ncbi_acc=NBK66049&ncbi_domain=pdqcis&ncbi_report=record&ncbi_type=fulltext&ncbi_objectid=&ncbi_pcid=/NBK66049.2/&ncbi_pagename=Fatigue (PDQ®) - PDQ Cancer Information Summaries - NCBI Bookshelf&ncbi_bookparttype=chapter&ncbi_app=bookshelf" /></noscript>
|
|
|
|
|
|
<!-- usually for JS scripts at page bottom -->
|
|
<!--<component id="PageFixtures" label="styles"></component>-->
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal104 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4209313/4212053/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
|
|
</html> |